

# Management of glioblastoma: State of the art and future

Ca-A Cancer Journal for Clinicians

70, 299-312

DOI: [10.3322/caac.21613](https://doi.org/10.3322/caac.21613)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Radiation Effects on Brain Extracellular Matrix. <i>Frontiers in Oncology</i> , 2020, 10, 576701.	2.8	13
2	Quantitative Imaging Parameters of Contrast-Enhanced Micro-Computed Tomography Correlate with Angiogenesis and Necrosis in a Subcutaneous C6 Glioma Model. <i>Cancers</i> , 2020, 12, 3417.	3.7	2
3	Neuroprotective Effects of Quercetin in Pediatric Neurological Diseases. <i>Molecules</i> , 2020, 25, 5597.	3.8	21
4	Effect of 1 $\alpha$ ,25(OH) $_2$ Vitamin D3 in Mutant P53 Glioblastoma Cells: Involvement of Neutral Sphingomyelinase1. <i>Cancers</i> , 2020, 12, 3163.	3.7	11
5	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 785-795.	2.4	23
6	PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages. <i>Frontiers in Immunology</i> , 2020, 11, 588552.	4.8	80
7	A Hematological-Related Prognostic Scoring System for Patients With Newly Diagnosed Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 591352.	2.8	3
8	Beyond TNBC: Repositioning of Clofazimine Against a Broad Range of Wnt-Dependent Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 602817.	2.8	16
9	Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 604121.	2.8	55
10	Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study. <i>Frontiers in Oncology</i> , 2020, 10, 593461.	2.8	10
11	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021, 499, 60-72.	7.2	194
12	Surgical Adjuncts for Glioblastoma. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 83-91.	1.7	1
13	Is This Really a Glioblastoma?. , 2021, , 163-171.		0
14	Recent incidence trend of elderly patients with glioblastoma in the United States, 2000â€“2017. <i>BMC Cancer</i> , 2021, 21, 54.	2.6	36
15	Glioblastoma: What can we do for these patients today and what will we be able to do in the future?. <i>Progress in Brain Research</i> , 2021, 265, 99-118.	1.4	0
16	Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient. <i>Progress in Brain Research</i> , 2021, 265, 407-414.	1.4	2
17	Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma. <i>Oncolimmunology</i> , 2021, 10, 1983306.	4.6	11
18	Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments. <i>Frontiers in Oncology</i> , 2020, 10, 614295.	2.8	51

#	ARTICLE	IF	CITATIONS
19	Therapeutic Quadrisected Annular Array for Improving Magnetic Resonance Compatibility. IEEE Transactions on Biomedical Engineering, 2022, 69, 199-208.	4.2	1
20	NEAT1 as a competing endogenous RNA in tumorigenesis of various cancers: Role, mechanism and therapeutic potential. International Journal of Biological Sciences, 2021, 17, 3428-3440.	6.4	45
21	Epidermal Growth Factor Receptor and its Oncogenic <i>EGFRvIII</i> Variant in Benign and Malignant Brain Tumors. Anticancer Research, 2021, 41, 983-991.	1.1	2
22	Impact of calcitriol and an AKT inhibitor, AT7867, on survival of rat C6 glioma cells. Biotechnology and Biotechnological Equipment, 2021, 35, 730-738.	1.3	1
23	Network pharmacological mechanism of Cinobufotalin against glioma. Progress in Brain Research, 2021, 265, 119-137.	1.4	3
24	Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma. Frontiers in Oncology, 2020, 10, 612385.	2.8	23
25	An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential GSK3 $\beta$ /I $\chi$ 2-Catenin/STAT3/CD44 Suppressor with Anti-Glioblastoma Properties. International Journal of Molecular Sciences, 2021, 22, 2464.	4.1	18
26	Double-targeting CDCA8 and E2F1 inhibits the growth and migration of malignant glioma. Cell Death and Disease, 2021, 12, 146.	6.3	15
27	Preoperative Predictors of Early Mortality Risk in Isocitrate Dehydrogenase-Wild-Type Glioblastoma Patients Treated with Standard Therapy. Cancer Management and Research, 2021, Volume 13, 1159-1168.	1.9	5
28	Recent insight into the role of RING-finger E3 ligases in glioma. Biochemical Society Transactions, 2021, 49, 519-529.	3.4	2
29	Multi-Channel RF Supervision Module for Thermal Magnetic Resonance Based Cancer Therapy. Cancers, 2021, 13, 1001.	3.7	8
30	The role of m6A modification in the biological functions and diseases. Signal Transduction and Targeted Therapy, 2021, 6, 74.	17.1	718
31	A Five Immune-Related lncRNA Signature as a Prognostic Target for Glioblastoma. Frontiers in Molecular Biosciences, 2021, 8, 632837.	3.5	15
32	Anticancer activity of the plant flavonoid luteolin against preclinical models of various cancers and insights on different signalling mechanisms modulated. Phytotherapy Research, 2021, 35, 3509-3532.	5.8	64
33	Characterizing the Genomic Landscape of Brain Glioma With Circulating Tumor DNA From Tumor In Situ Fluid. Frontiers in Oncology, 2021, 11, 584988.	2.8	9
34	Residual Disease in Glioma Recurrence: A Dangerous Liaison with Senescence. Cancers, 2021, 13, 1560.	3.7	14
35	The Triad Hsp60-miRNAs-Extracellular Vesicles in Brain Tumors: Assessing Its Components for Understanding Tumorigenesis and Monitoring Patients. Applied Sciences (Switzerland), 2021, 11, 2867.	2.5	12
36	Cellular Trojan horses for delivery of nanomedicines to brain tumors: where do we stand and what is next?. Nanomedicine, 2021, 16, 517-522.	3.3	6

#	ARTICLE	IF	CITATIONS
37	Mitoxantrone-Loaded PLGA Nanoparticles for Increased Sensitivity of Glioblastoma Cancer Cell to TRAIL-Induced Apoptosis. <i>Journal of Pharmaceutical Innovation</i> , 2022, 17, 207-214.	2.4	5
38	Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1367.	2.4	18
39	Targeting the Complement Pathway in Malignant Glioma Microenvironments. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 657472.	3.7	12
40	Glutathione S-Transferases in Cancer. <i>Antioxidants</i> , 2021, 10, 701.	5.1	94
41	Partial response to Chinese patent medicine Kangliu pill for adult glioblastoma: A case report and review of the literature. <i>World Journal of Clinical Cases</i> , 2021, 9, 2845-2853.	0.8	1
42	Overcoming TRAIL Resistance for Glioblastoma Treatment. <i>Biomolecules</i> , 2021, 11, 572.	4.0	17
43	AGAP2-AS1 May Promote the Occurrence and Development of Glioblastoma by Sponging miR-9-5p: Evidence From a ceRNA Network. <i>Frontiers in Oncology</i> , 2021, 11, 607989.	2.8	4
44	A Critical Review of PET Tracers Used for Brain Tumor Imaging. <i>PET Clinics</i> , 2021, 16, 219-231.	3.0	8
45	Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment. <i>Biochemical and Biophysical Research Communications</i> , 2021, 551, 38-45.	2.1	4
46	Glioma-on-a-Chip Models. <i>Micromachines</i> , 2021, 12, 490.	2.9	19
47	CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDKN1A Transcription. <i>Frontiers in Oncology</i> , 2021, 11, 638802.	2.8	3
48	miR-1258 Attenuates Tumorigenesis Through Targeting E2F1 to Inhibit PCNA and MMP2 Transcription in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 671144.	2.8	7
49	Establishment of a Novel Temozolomide Resistant Subline of Glioblastoma Multiforme Cells and Comparative Transcriptome Analysis With Parental Cells. <i>Anticancer Research</i> , 2021, 41, 2333-2347.	1.1	3
50	Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors. <i>Cells</i> , 2021, 10, 1142.	4.1	12
51	EMP3 mediates glioblastoma-associated macrophage infiltration to drive T cell exclusion. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 160.	8.6	25
52	Dynein Light Chain Protein Tctex1: A Novel Prognostic Marker and Molecular Mediator in Glioblastoma. <i>Cancers</i> , 2021, 13, 2624.	3.7	5
53	Viral Gene Therapy for Glioblastoma Multiforme: A Promising Hope for the Current Dilemma. <i>Frontiers in Oncology</i> , 2021, 11, 678226.	2.8	6
54	A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662302.	2.8	10

#	ARTICLE	IF	CITATIONS
55	A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. <i>Neuro-Oncology</i> , 2021, 23, 1736-1749.	1.2	44
56	Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study. <i>Frontiers in Immunology</i> , 2021, 12, 632547.	4.8	13
57	Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients. <i>Molecular Medicine</i> , 2021, 27, 52.	4.4	10
58	Opposed Interplay between IDH1 Mutations and the WNT/ $\beta$ -Catenin Pathway: Added Information for Glioma Classification. <i>Biomedicines</i> , 2021, 9, 619.	3.2	5
59	A retrospective analysis of the risk factors affecting recurrence time in patients with recurrent glioblastoma. <i>Annals of Palliative Medicine</i> , 2021, 10, 38-38.	1.2	4
60	Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist. <i>Cell Death and Disease</i> , 2021, 12, 647.	6.3	12
61	A Key Pathway to Cancer Resilience: The Role of Autophagy in Glioblastomas. <i>Frontiers in Oncology</i> , 2021, 11, 652133.	2.8	4
62	Pro- and Antiangiogenic Factors in Gliomas: Implications for Novel Therapeutic Possibilities. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6126.	4.1	11
63	Twenty Years After Glioblastoma Multiforme Diagnosis: A Case of Long-Term Survival. <i>Cureus</i> , 2021, 13, e16061.	0.5	1
64	Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems. <i>Life Sciences</i> , 2021, 275, 119368.	4.3	63
65	Sphingosine 1-Phosphate Liposomes for Targeted Nitric Oxide Delivery to Mediate Anticancer Effects against Brain Glioma Tumors. <i>Advanced Materials</i> , 2021, 33, e2101701.	21.0	41
66	Human Glioblastoma Visualization: Triple Receptor-Targeting Fluorescent Complex of Dye, SIWV Tetra-Peptide, and Serum Albumin Protein. <i>ACS Sensors</i> , 2021, 6, 2270-2280.	7.8	12
67	The Emerging Roles of circFOXO3 in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 659417.	3.7	12
68	Dual Role of Integrin Alpha-6 in Glioblastoma: Supporting Stemness in Proneural Stem-Like Cells While Inducing Radioresistance in Mesenchymal Stem-Like Cells. <i>Cancers</i> , 2021, 13, 3055.	3.7	6
69	Current research advances in microRNA-mediated regulation of Krüppel-like factor 4 in cancer: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 948-948.	1.7	1
70	BRD4: An emerging prospective therapeutic target in glioma. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 1-14.	4.4	30
71	Extrinsic factors associated with the response to immunotherapy in glioblastoma. <i>Cancer Letters</i> , 2021, 511, 47-55.	7.2	2
72	Can we rely on synthetic pharmacotherapy for the treatment of glioblastoma?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1983-1994.	1.8	2

#	ARTICLE	IF	CITATIONS
73	Oral SMEDDS promotes lymphatic transport and mesenteric lymph nodes target of chlorogenic acid for effective T-cell antitumor immunity. , 2021, 9, e002753.		18
74	Neurocytological Advances in the Treatment of Glioblastoma Multiforme. Cureus, 2021, 13, e16301.	0.5	2
75	The New PI3K/mTOR Inhibitor GNE-477 Inhibits the Malignant Behavior of Human Glioblastoma Cells. Frontiers in Pharmacology, 2021, 12, 659511.	3.5	2
76	METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner. Frontiers in Oncology, 2021, 11, 702983.	2.8	25
77	Alterations of the Gut Microbiome in Recurrent Malignant Gliomas Patients Received Bevacizumab and Temozolomide Combination Treatment and Temozolomide Monotherapy. Indian Journal of Microbiology, 2022, 62, 23-31.	2.7	3
78	MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy. Frontiers in Oncology, 2021, 11, 703442.	2.8	17
79	Chemotherapy-Induced Degradation of Glycosylated Components of the Brain Extracellular Matrix Promotes Glioblastoma Relapse Development in an Animal Model. Frontiers in Oncology, 2021, 11, 713139.	2.8	8
80	A Deep Dive: SIWV Tetra-Peptide Enhancing the Penetration of Nanotherapeutics into the Glioblastoma. ACS Biomaterials Science and Engineering, 2022, 8, 4163-4174.	5.2	6
81	Glioblastoma: clinical presentation, diagnosis, and management. BMJ, The, 2021, 374, n1560.	6.0	133
82	Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma. Frontiers in Immunology, 2021, 12, 650105.	4.8	15
83	Tumor Associated Macrophages, as the Dominant Immune Cells, Are an Indispensable Target for Immunologically Cold Tumorâ€”Glioma Therapy?. Frontiers in Cell and Developmental Biology, 2021, 9, 706286.	3.7	43
84	VMP1, a novel prognostic biomarker, contributes to glioma development by regulating autophagy. Journal of Neuroinflammation, 2021, 18, 165.	7.2	10
85	Nanotechnologyâ€”Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVIDâ€”19 Vaccines. Small Methods, 2021, 5, 2100402.	8.6	45
86	Development and Validation of a Long-Term 3D Glioblastoma Cell Culture in Alginate Microfibers as a Novel Bio-Mimicking Model System for Preclinical Drug Testing. Brain Sciences, 2021, 11, 1025.	2.3	14
87	FBXW7 induces apoptosis in glioblastoma cells by regulating HDAC7. Cell Biology International, 2021, 45, 2150-2158.	3.0	3
88	Connexin 43 and Sonic Hedgehog Pathway Interplay in Glioblastoma Cell Proliferation and Migration. Biology, 2021, 10, 767.	2.8	20
89	EP2 Antagonists (2011â€”2021): A Decadeâ€”s Journey from Discovery to Therapeutics. Journal of Medicinal Chemistry, 2021, 64, 11816-11836.	6.4	21
90	AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide. Scientific Reports, 2021, 11, 17348.	3.3	12

#	ARTICLE	IF	CITATIONS
91	Targeting Non-coding RNA for Glioblastoma Therapy: The Challenge of Overcomes the Blood-Brain Barrier. <i>Frontiers in Medical Technology</i> , 2021, 3, 678593.	2.5	11
92	Arbutin exerts anticancer activity against rat C6 glioma cells by inducing apoptosis and inhibiting the inflammatory markers and P13/Akt/mTOR cascade. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22857.	3.0	6
93	The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme. <i>Future Oncology</i> , 2021, 17, 4405-4413.	2.4	5
94	Influence of scalp block on oncological outcomes of high-grade glioma in adult patients with and without isocitrate dehydrogenase-1 mutation. <i>Scientific Reports</i> , 2021, 11, 16489.	3.3	1
95	Role of microRNAs in glioblastoma. <i>Oncotarget</i> , 2021, 12, 1707-1723.	1.8	38
96	Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 643-647.	5.9	7
97	Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma. <i>Pathology and Oncology Research</i> , 2021, 27, 1609825.	1.9	5
98	Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 729359.	4.8	10
99	Gene clusters based on OLIG2 and CD276 could distinguish molecular profiling in glioblastoma. <i>Journal of Translational Medicine</i> , 2021, 19, 404.	4.4	2
100	Prognostic and Predictive Biomarkers in Gliomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10373.	4.1	110
101	Bone Metastases of Glioblastoma: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2021, 11, 705455.	2.8	11
102	Clinical Targeting of Altered Metabolism in High-Grade Glioma. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 386-394.	2.0	6
103	Latest Innovations and Nanotechnologies with Curcumin as a Nature-Inspired Photosensitizer Applied in the Photodynamic Therapy of Cancer. <i>Pharmaceutics</i> , 2021, 13, 1562.	4.5	27
104	Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics. <i>Oncogene</i> , 2021, 40, 6059-6070.	5.9	13
105	Exosome-mediated transfer of MIF confers temozolomide resistance by regulating TIMP3/PI3K/AKT axis in gliomas. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 114-128.	4.4	24
106	ELTD1 as a Multi-Focal Target for Malignant Gliomas: Pre-Clinical Studies. <i>Neuro-Oncology Advances</i> , 2021, 3, vda132.	0.7	1
107	Macrophage/microglia-derived IL-1 $\beta$ induces glioblastoma growth via the STAT3/NF- $\kappa$ B pathway. <i>Human Cell</i> , 2022, 35, 226-237.	2.7	19
108	In Vitro and In Vivo Enhancement of Temozolomide Effect in Human Glioblastoma by Non-Invasive Application of Cold Atmospheric Plasma. <i>Cancers</i> , 2021, 13, 4485.	3.7	26

#	ARTICLE	IF	CITATIONS
109	Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, 343-357.	2.5	7
110	Antioxidant responses related to temozolomide resistance in glioblastoma. <i>Neurochemistry International</i> , 2021, 149, 105136.	3.8	17
111	Hydrogel loading functionalized PAMAM/shRNA complex for postsurgical glioblastoma treatment. <i>Journal of Controlled Release</i> , 2021, 338, 583-592.	9.9	18
112	Vessel-Targeting Nanoclovers Enable Noninvasive Delivery of Magnetic Hyperthermiaâ€“Chemotherapy Combination for Brain Cancer Treatment. <i>Nano Letters</i> , 2021, 21, 8111-8118.	9.1	19
113	Versatile metal-phenolic network nanoparticles for multitargeted combination therapy and magnetic resonance tracing in glioblastoma. <i>Biomaterials</i> , 2021, 278, 121163.	11.4	47
114	Intraoperative radiotherapy for glioblastoma: A systematic review of techniques and outcomes. <i>Journal of Clinical Neuroscience</i> , 2021, 93, 36-41.	1.5	7
115	N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents: Synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2021, 226, 113817.	5.5	4
116	Circular RNA circLGMN facilitates glioblastoma progression by targeting miR-127-3p/LGMN axis. <i>Cancer Letters</i> , 2021, 522, 225-237.	7.2	25
117	Overcoming drug resistance in glioblastoma: new options in sight?. , 2021, 4, 512-516.		3
118	Chromatin-regulating genes are associated with postoperative prognosis and isocitrate dehydrogenase mutation in astrocytoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1594-1594.	1.7	4
119	An Immune Gene-Related Five-lncRNA Signature for to Predict Glioma Prognosis. <i>Frontiers in Genetics</i> , 2020, 11, 612037.	2.3	24
120	A Five-lncRNAs Signature-Derived Risk Score Based on TCGA and CGGA for Glioblastoma: Potential Prospects for Treatment Evaluation and Prognostic Prediction. <i>Frontiers in Oncology</i> , 2020, 10, 590352.	2.8	15
121	Multifunctional nanoparticle PEGâ€“Ce6â€“Gd for MRIâ€“guided photodynamic therapy. <i>Oncology Reports</i> , 2020, 45, 547-556.	2.6	16
122	SP1-upregulated LBX2-AS1 promotes the progression of glioma by targeting the miR-491-5p/LIF axis. <i>Journal of Cancer</i> , 2021, 12, 6989-7002.	2.5	12
123	Anti-glioblastoma effects of nanomicelle-curcumin plus erlotinib. <i>Food and Function</i> , 2021, 12, 10926-10937.	4.6	21
124	Phospholipase CÎ³1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients. <i>Laboratory Investigation</i> , 2022, 102, 143-153.	3.7	14
125	Targeting glioblastoma stem cells: The first step of photodynamic therapy. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 36, 102585.	2.6	9
126	A novel biphenyl diester derivative, AB38b, inhibits glioblastoma cell growth via the ROS-AKT/mTOR pathway. <i>Biochemical Pharmacology</i> , 2021, 194, 114795.	4.4	3



#	ARTICLE	IF	CITATIONS
127	Stratification by Tumor Grade Groups in a Holistic Evaluation of Machine Learning for Brain Tumor Segmentation. <i>Frontiers in Neuroscience</i> , 2021, 15, 740353.	2.8	3
128	Mass transfer of anti-cancer drug delivery to brain tumors by a multiple emulsion-based implant. <i>AIChE Journal</i> , 2022, 68, e17501.	3.6	7
129	Evolving Landscape of Long Non-coding RNAs in Cerebrospinal Fluid: A Key Role From Diagnosis to Therapy in Brain Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 737670.	3.7	2
130	Upregulated Expression of Cancer-Derived Immunoglobulin G Is Associated With Progression in Glioma. <i>Frontiers in Oncology</i> , 2021, 11, 758856.	2.8	11
131	Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence. <i>Frontiers in Oncology</i> , 2021, 11, 742037.	2.8	7
132	Prognosis and Immunotherapy Significances of a Cancer-Associated Fibroblasts-Related Gene Signature in Gliomas. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 721897.	3.7	13
133	Carbon Dots: An Innovative Tool for Drug Delivery in Brain Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11783.	4.1	54
134	Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies. <i>Advanced Drug Delivery Reviews</i> , 2021, 179, 113999.	13.7	32
135	Lipoprotein-biomimetic nanostructure enables tumor-targeted penetration delivery for enhanced photo-gene therapy towards glioma. <i>Bioactive Materials</i> , 2022, 13, 286-299.	15.6	19
136	Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression. <i>European Journal of Medicinal Chemistry</i> , 2022, 227, 113908.	5.5	4
137	Antiproliferative activity of CD44 siRNA-PEI-PEG nanoparticles in glioblastoma: involvement of AKT signaling. <i>Research in Pharmaceutical Sciences</i> , 2022, 17, 78.	1.8	5
138	Glucose oxidase and L-arginine functionalized black phosphorus nanosheets for multimodal targeted therapy of glioblastoma. <i>Chemical Engineering Journal</i> , 2022, 430, 132898.	12.7	21
139	NOX4-derived ROS-induced overexpression of FOXM1 regulates aerobic glycolysis in glioblastoma. <i>BMC Cancer</i> , 2021, 21, 1181.	2.6	19
140	Development and Verification of the Amino Metabolism-Related and Immune-Associated Prognosis Signature in Gliomas. <i>Frontiers in Oncology</i> , 2021, 11, 774332.	2.8	3
141	A Specific Peptide Vaccine Against IDH1(R132H) Glioma. <i>Neuroscience Bulletin</i> , 2021, , 1.	2.9	2
142	Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	45
143	Predictors of Citation Rates in High-Impact Glioblastoma Clinical Trials. <i>Cureus</i> , 2021, 13, e19229.	0.5	2
144	A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 756817.	2.8	4

#	ARTICLE	IF	CITATIONS
145	Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11938.	4.1	11
146	HOXC6/8/10/13 predict poor prognosis and associate with immune infiltrations in glioblastoma. <i>International Immunopharmacology</i> , 2021, 101, 108293.	3.8	6
147	Expression and clinical significance of in glioma. <i>International Journal of Clinical and Experimental Pathology</i> , 2021, 14, 938-955.	0.5	0
148	TRAM2 promotes the malignant progression of glioma through PI3K/AKT/mTOR pathway. <i>Biochemical and Biophysical Research Communications</i> , 2022, 586, 34-41.	2.1	9
149	Targeting alpha2,3-sialylated glycan in glioma stem-like cells by Maackia amurensis lectin-II: A promising strategy for glioma treatment. <i>Experimental Cell Research</i> , 2022, 410, 112949.	2.6	6
150	Extracranial multiorgan metastasis from primary glioblastoma: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 10300-10307.	0.8	3
151	New Autophagy-Ferroptosis Gene Signature Predicts Survival in Glioma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 739097.	3.7	2
152	Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 400.	17.1	86
153	Research Progress of circRNAs in Glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 791892.	3.7	12
154	Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. <i>Advanced Drug Delivery Reviews</i> , 2022, 181, 114033.	13.7	5
155	Poly(allylguanidine)-Coated Surfaces Regulate TGF- $\beta$ 2 in Glioblastoma Cells to Induce Apoptosis via NF- $\kappa$ B Pathway Activation. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 59400-59410.	8.0	5
156	Comprehensive analysis of expression, prognosis and immune infiltration for TIMPs in glioblastoma. <i>BMC Neurology</i> , 2021, 21, 447.	1.8	8
158	Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study. <i>Journal of Neuro-Oncology</i> , 2021, 155, 343-351.	2.9	4
159	Gasdermin D Is a Novel Prognostic Biomarker and Relates to TMZ Response in Glioblastoma. <i>Cancers</i> , 2021, 13, 5620.	3.7	12
160	For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. , 2021, 9, e003679.		11
161	A Microenvironment Regulator for Filling the Clinical Treatment Gap after a Glioblastoma Operation. <i>Advanced Healthcare Materials</i> , 2022, 11, e2101578.	7.6	7
162	Editorial: Recent 3D Tumor Models for Testing Immune-Mediated Therapies. <i>Frontiers in Immunology</i> , 2021, 12, 798493.	4.8	2
163	Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 55851-55861.	8.0	7

#	ARTICLE	IF	CITATIONS
164	Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. <i>Bioengineered</i> , 2021, 12, 10791-10798.	3.2	9
165	Immunohistochemical expression of HIF-1 $\alpha$ , IDH1 and TP53: Prognostic profile of Moroccan patients with diffuse glioma. <i>Journal of Chemical Neuroanatomy</i> , 2022, 119, 102056.	2.1	3
166	Hsp90 Induces Acsl4-Dependent Ferroptosis Via Dephosphorylate Ser637 at Drp1 in Glioma Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
167	Design of Bio-Responsive Hyaluronic Acid-Doxorubicin Conjugates for the Local Treatment of Glioblastoma. <i>Pharmaceutics</i> , 2022, 14, 124.	4.5	15
168	Developing and validating a deep learning and radiomic model for glioma grading using multiplanar reconstructed magnetic resonance contrast-enhanced T1-weighted imaging: a robust, multi-institutional study. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 1517-1528.	2.0	18
169	BACH1 as a potential target for immunotherapy in glioblastomas. <i>International Immunopharmacology</i> , 2022, 103, 108451.	3.8	11
170	In vitro and in vivo evaluation of 211At-labeled fibroblast activation protein inhibitor for glioma treatment. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 55, 116600.	3.0	16
171	Scale-adaptive super-feature based MetricUNet for brain tumor segmentation. <i>Biomedical Signal Processing and Control</i> , 2022, 73, 103442.	5.7	19
172	The CBL-LSD1-CXCL8 axis regulates methionine metabolism in glioma. <i>Cytokine</i> , 2022, 151, 155789.	3.2	2
173	The transcript ENST00000444125 of lncRNA LINC01503 promotes cancer stem cell properties of glioblastoma cells via reducing FBXW1 mediated GLI2 degradation. <i>Experimental Cell Research</i> , 2022, 412, 113009.	2.6	9
174	Downregulation of USP33 inhibits Slit/Robo signaling pathway and is associated with poor patient survival of glioma. <i>Journal of Neurosurgical Sciences</i> , 2023, 67, .	0.6	3
175	SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ $\beta$ -catenin pathways imbalances. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 39.	8.6	19
176	Biomaterials: Emerging systems for study and treatment of glioblastoma. <i>Neurology Perspectives</i> , 2022, 2, S31-S42.	0.5	6
177	Combining nanotechnology with the multifunctional roles of neutrophils against cancer and inflammatory disease. <i>Nanoscale</i> , 2022, 14, 1621-1645.	5.6	3
178	Preoperative Stereotactic Radiosurgery for Glioblastoma. <i>Biology</i> , 2022, 11, 194.	2.8	7
179	3BDO inhibits the proliferation, epithelial-mesenchymal transition (EMT), and stemness via suppressing survivin in human glioblastoma cells. <i>Journal of Cancer</i> , 2022, 13, 1203-1213.	2.5	0
180	The Role of Graphene Oxide Nanocarriers in Treating Gliomas. <i>Frontiers in Oncology</i> , 2022, 12, 736177.	2.8	9
181	In vitro antitumor activity of dialkylamine-1,4-naphthoquinones on human glioblastoma multiforme cells. <i>New Journal of Chemistry</i> , 0, , .	2.8	1

#	ARTICLE	IF	CITATIONS
182	A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma. <i>Neuro-Oncology Practice</i> , 2022, 9, 193-200.	1.6	11
183	IL-33 induces ADAMTS5 expression and cell migration in glioblastoma multiforme. <i>Medical Oncology</i> , 2022, 39, 22.	2.5	3
184	Chlorin Endogenous to the North Pacific Brittle Star <i>Ophiura sarsii</i> for Photodynamic Therapy Applications in Breast Cancer and Glioblastoma Models. <i>Biomedicines</i> , 2022, 10, 134.	3.2	3
185	Impediment of Cerebrospinal Fluid Drainage Through Glymphatic System in Glioma. <i>Frontiers in Oncology</i> , 2021, 11, 790821.	2.8	8
186	A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 812422.	3.7	5
187	Novel Immune-Related Gene-Based Signature Characterizing an Inflamed Microenvironment Predicts Prognosis and Radiotherapy Efficacy in Glioblastoma. <i>Frontiers in Genetics</i> , 2021, 12, 736187.	2.3	3
188	A Novel 16-Genes Signature Scoring System as Prognostic Model to Evaluate Survival Risk in Patients with Glioblastoma. <i>Biomedicines</i> , 2022, 10, 317.	3.2	11
189	Comprehensive histological imaging of native microbiota in human glioma. <i>Journal of Biophotonics</i> , 2022, 15, e202100351.	2.3	14
190	Biological evaluation of complexes of cyclopentadienyl $M(CO)_3^+$ ( $M = Re, 99mTc$ ) with high blood-brain barrier penetration potential as brain cancer agents. <i>Investigational New Drugs</i> , 2022, , 1.	2.6	2
191	Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1143.	4.1	5
192	IGF2BP2 Induces U251 Glioblastoma Cell Chemoresistance by Inhibiting FOXO1-Mediated PID1 Expression Through Stabilizing lncRNA DANCR. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 659228.	3.7	14
193	Nanomedicine in Clinical Photodynamic Therapy for the Treatment of Brain Tumors. <i>Biomedicines</i> , 2022, 10, 96.	3.2	10
194	Paradol Induces Cell Cycle Arrest and Apoptosis in Glioblastoma Cells. <i>Nutrition and Cancer</i> , 2022, 74, 3007-3014.	2.0	2
195	Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma. <i>Journal of Neurosurgery</i> , 2022, 137, 914-923.	1.6	7
196	Exploring the potential biomarkers for prognosis of glioblastoma via weighted gene co-expression network analysis. <i>PeerJ</i> , 2022, 10, e12768.	2.0	1
197	MR susceptibility imaging for detection of tumor-associated macrophages in Glioblastoma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 645-653.	2.9	2
198	Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes. <i>Neurosurgical Focus</i> , 2022, 52, E5.	2.3	11
199	Immunoregulatory effects of glioma-associated stem cells on the glioblastoma peritumoral microenvironment: a differential PD-L1 expression from core to periphery?. <i>Neurosurgical Focus</i> , 2022, 52, E4.	2.3	9

#	ARTICLE	IF	CITATIONS
200	Metabolic characteristics of [18F]fluoroboronotyrosine (FBY) PET in malignant brain tumors. Nuclear Medicine and Biology, 2022, 106-107, 80-87.	0.6	11
201	Nanomedicine for brain cancer. Advanced Drug Delivery Reviews, 2022, 182, 114115.	13.7	57
202	SPI1-induced downregulation of FTO promotes GBM progression by regulating pri-miR-10a processing in an m6A-dependent manner. Molecular Therapy - Nucleic Acids, 2022, 27, 699-717.	5.1	23
203	LncRNA NEAT1 facilitates glioma progression via stabilizing PGK1. Journal of Translational Medicine, 2022, 20, 80.	4.4	20
204	A Multi-Compartment Model of Glioma Response to Fractionated Radiation Therapy Parameterized via Time-Resolved Microscopy Data. Frontiers in Oncology, 2022, 12, 811415.	2.8	1
205	Nose-to-brain delivery of simvastatin mediated by chitosan-coated lipid-core nanocapsules allows for the treatment of glioblastoma in vivo. International Journal of Pharmaceutics, 2022, 616, 121563.	5.2	8
206	Glioma targeted therapy: insight into future of molecular approaches. Molecular Cancer, 2022, 21, 39.	19.2	274
207	Clinical Significance and Immune Landscape of a Pyroptosis-Derived LncRNA Signature for Glioblastoma. Frontiers in Cell and Developmental Biology, 2022, 10, 805291.	3.7	14
208	Cirsilineol inhibits cell growth and induces apoptosis in glioma C6 cells via inhibiting MAPK and PI3K/Akt/mTOR signaling pathways. Applied Nanoscience (Switzerland), 0, , 1.	3.1	2
209	Case Report: H3K27M-Mutant Glioblastoma Simultaneously Present in the Brain and Long-Segment Spinal Cord Accompanied by Acute Pulmonary Embolism. Frontiers in Oncology, 2021, 11, 763854.	2.8	1
210	Functions of RNF Family in the Tumor Microenvironment and Drugs Prediction in Grade II/III Gliomas. Frontiers in Cell and Developmental Biology, 2021, 9, 754873.	3.7	2
211	Radiotherapy-induced remodeling of the tumor microenvironment by stromal cells. Seminars in Cancer Biology, 2022, 86, 846-856.	9.6	27
212	A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitroene-based OKN-007. Journal of Cellular and Molecular Medicine, 2022, 26, 570-582.	3.6	3
213	Polyphenolic Acetates as Potential Therapeutics and Adjuvant in Radiotherapy of Cancer. , 2022, , 1-17.		0
214	HLA-E and HLA-F Are Overexpressed in Glioblastoma and HLA-E Increased After Exposure to Ionizing Radiation. Cancer Genomics and Proteomics, 2022, 19, 151-162.	2.0	11
215	Blockade of Nuclear Factor- $\kappa$ B (NF- $\kappa$ B) Pathway Using Bay 11-7082 Enhances Arsenic Trioxide-Induced Antiproliferative Activity in U87 Glioblastoma Cells. Reports of Biochemistry and Molecular Biology, 2022, 10, 602-613.	1.4	0
216	Targeting HOTAIRM1 Ameliorates Glioblastoma by Disturbing Mitochondrial Oxidative Phosphorylation and Serine Metabolism. SSRN Electronic Journal, 0, , .	0.4	0
217	PKM2 Is Overexpressed in Glioma Tissues, and Its Inhibition Highly Increases Late Apoptosis in U87MG Cells With Low-density Specificity. In Vivo, 2022, 36, 694-703.	1.3	7

#	ARTICLE	IF	CITATIONS
218	Rational design of ROS-responsive nanocarriers for targeted X-ray-induced photodynamic therapy and cascaded chemotherapy of intracranial glioblastoma. <i>Nanoscale</i> , 2022, 14, 5054-5067.	5.6	11
219	Identification of key genes associated with survival of glioblastoma multiforme using integrated analysis of TCGA datasets. <i>Computer Methods and Programs in Biomedicine Update</i> , 2022, 2, 100051.	3.7	7
220	New prognostic biomarker CMTM3 in low grade glioma and its immune infiltration. <i>Annals of Translational Medicine</i> , 2022, 10, 206-206.	1.7	7
221	Tannic Acid Attenuates Peripheral and Brain Changes in a Preclinical Rat Model of Glioblastoma by Modulating Oxidative Stress and Purinergic Signaling. <i>Neurochemical Research</i> , 2022, 47, 1541-1552.	3.3	5
222	Cell-based immunotherapy of glioblastoma multiforme (Review). <i>Oncology Letters</i> , 2022, 23, 133.	1.8	6
223	Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy. <i>Cancers</i> , 2022, 14, 902.	3.7	39
224	Shape-Mediated Magnetocrystalline Anisotropy and Relaxation Controls by Cobalt Ferrite Core-Shell Heterostructures for Magnetothermal Penetration Delivery. <i>Advanced Materials Interfaces</i> , 0, , 2200022.	3.7	1
225	MicroRNA-22: a Novel and Potent Biological Therapeutics in Neurological Disorders. <i>Molecular Neurobiology</i> , 2022, 59, 2694-2701.	4.0	15
226	PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. <i>Cancers</i> , 2022, 14, 1003.	3.7	18
227	Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2022, 157, 15-26.	2.9	3
228	Glioblastoma Vasculature: From its Critical Role in Tumor Survival to Relevant in Vitro Modelling. <i>Frontiers in Drug Delivery</i> , 2022, 2, .	1.6	2
229	Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma. <i>Cancer Cell International</i> , 2022, 22, 87.	4.1	8
230	CRISPR screening of E3 ubiquitin ligases reveals Ring Finger Protein 185 as a novel tumor suppressor in glioblastoma repressed by promoter hypermethylation and miR-587. <i>Journal of Translational Medicine</i> , 2022, 20, 96.	4.4	6
231	A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2658-2671.	12.0	34
232	Emerging Glycation-Based Therapeutics-Glyoxalase 1 Inducers and Glyoxalase 1 Inhibitors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2453.	4.1	18
233	Production and Stabilization of Specific Upregulated Long Noncoding RNA HOXD-AS2 in Glioblastomas Are Mediated by TFE3 and miR-661, Respectively. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2828.	4.1	1
234	Comprehensive Analysis of the Tumor Immune Microenvironment Landscape in Glioblastoma Reveals Tumor Heterogeneity and Implications for Prognosis and Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 820673.	4.8	10
235	RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 1261-1272.	1.2	6



#	ARTICLE	IF	CITATIONS
236	Exploring the Role of Transglutaminase in Patients with Glioblastoma: Current Perspectives. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 277-290.	2.0	5
237	Enhancement of CD70-specific CAR T treatment by IFN- $\gamma$ released from oHSV-1-infected glioblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2433-2448.	4.2	11
238	Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy. <i>Neuro-Oncology</i> , 2022, 24, 1871-1883.	1.2	35
239	Angiogenesis-Related Gene Signature-Derived Risk Score for Glioblastoma: Prospects for Predicting Prognosis and Immune Heterogeneity in Glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 778286.	3.7	6
240	Research progress of anti-glioma chemotherapeutic drugs (Review). <i>Oncology Reports</i> , 2022, 47, .	2.6	12
241	Inhibition of GLI-Mediated Transcription by Cyclic Pyrrole-Imidazole Polyamide in Cancer Stem Cells. <i>Bulletin of the Chemical Society of Japan</i> , 2022, 95, 693-699.	3.2	10
242	Reciprocity of Cell Mechanics with Extracellular Stimuli: Emerging Opportunities for Translational Medicine. <i>Small</i> , 2022, 18, e2107305.	10.0	6
243	HOTTIP Mediated Therapy Resistance in Glioma Cells Involves Regulation of EMT-Related miR-10b. <i>Frontiers in Oncology</i> , 2022, 12, 873561.	2.8	6
244	CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas. <i>Scientific Reports</i> , 2022, 12, 4295.	3.3	20
245	Emerging MR Imaging and Spectroscopic Methods to Study Brain Tumor Metabolism. <i>Frontiers in Neurology</i> , 2022, 13, 789355.	2.4	8
247	The Role of Micro RNAs in Regulating PI3K/AKT Signaling Pathways in Glioblastoma. <i>Iranian Journal of Pathology</i> , 2022, 17, 122-136.	0.5	4
248	TMZ magnetic temperature-sensitive liposomes-mediated magnetothermal chemotherapy induces pyroptosis in glioblastoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 43, 102554.	3.3	16
249	Temporal muscle thickness as an independent prognostic imaging marker in newly diagnosed glioblastoma patients: A validation study. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac038.	0.7	6
250	Machine Learning in Differentiating Gliomas from Primary CNS Lymphomas: A Systematic Review, Reporting Quality, and Risk of Bias Assessment. <i>American Journal of Neuroradiology</i> , 2022, 43, 526-533.	2.4	7
251	Overexpression of prothymosin-alpha in glioma is associated with tumor aggressiveness and poor prognosis. <i>Bioscience Reports</i> , 2022, , .	2.4	4
252	The AlkB Family: Potential Prognostic Biomarkers and Therapeutic Targets in Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, 847821.	2.8	1
253	Bromodomain containing 4 transcriptionally activated Deltex E3 ubiquitin ligase 2 contributes to glioma progression and predicts an unfavorable prognosis. <i>Annals of Translational Medicine</i> , 2022, 10, 313-313.	1.7	6
254	Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2703-2715.	4.2	3

#	ARTICLE	IF	CITATIONS
255	Histone Deacetylase Inhibitors Impair Glioblastoma Cell Motility and Proliferation. <i>Cancers</i> , 2022, 14, 1897.	3.7	11
256	Weakly supervised brain tumor segmentation via semantic affinity deep neural network. , 2022, , .		2
257	Direct Current Electric Field Coordinates the Migration of BV2 Microglia via ERK/GSK3 $\beta$ /Cofilin Signaling Pathway. <i>Molecular Neurobiology</i> , 2022, 59, 3665-3677.	4.0	3
258	PSMG3 $\alpha$ AS1 enhances glioma resistance to temozolomide via stabilizing $\alpha$ -Myc in the nucleus. <i>Brain and Behavior</i> , 2022, 12, e2531.	2.2	3
259	Platelet-derived growth factor signalling in neurovascular function and disease. <i>International Journal of Biochemistry and Cell Biology</i> , 2022, 145, 106187.	2.8	4
260	Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment. <i>International Journal of Pharmaceutics</i> , 2022, 617, 121584.	5.2	4
261	Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme. <i>Neuroscience</i> , 2022, 491, 240-270.	2.3	22
262	Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer. <i>Journal of Controlled Release</i> , 2022, 346, 43-70.	9.9	17
263	Case-Control Studies in Neurosurgery: the Issue of Effect Estimates. <i>World Neurosurgery</i> , 2022, , .	1.3	0
264	Enhanced anti-angiogenic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model. <i>MAbs</i> , 2022, 14, 2057269.	5.2	8
265	Eliminating the original cargos of glioblastoma cell-derived small extracellular vesicles for efficient drug delivery to glioblastoma with improved biosafety. <i>Bioactive Materials</i> , 2022, 16, 204-217.	15.6	10
266	Novel Biomarker Genes for Prognosis of Survival and Treatment of Glioma. <i>Frontiers in Oncology</i> , 2021, 11, 667884.	2.8	9
267	Multiple Irradiation Affects Cellular and Extracellular Components of the Mouse Brain Tissue and Adhesion and Proliferation of Glioblastoma Cells in Experimental System In Vivo. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13350.	4.1	4
268	Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies. <i>Cells</i> , 2022, 11, 116.	4.1	9
269	Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13635.	4.1	4
270	A Comparison of Single- and Multiparametric MRI Models for Differentiation of Recurrent Glioblastoma from Treatment-Related Change. <i>Diagnostics</i> , 2021, 11, 2281.	2.6	0
271	Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1804-1804.	1.7	1
272	CYP1B1-AS1 Is a Novel Biomarker in Glioblastoma by Comprehensive Analysis. <i>Disease Markers</i> , 2021, 2021, 1-8.	1.3	3



#	ARTICLE	IF	CITATIONS
273	Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma. International Journal of Molecular Sciences, 2022, 23, 316.	4.1	11
275	Deciphering the Labyrinthine System of the Immune Microenvironment in Recurrent Glioblastoma: Recent Original Advances and Lessons from Clinical Immunotherapeutic Approaches. Cancers, 2021, 13, 6156.	3.7	8
276	Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment. Cells, 2021, 10, 3529.	4.1	16
277	Combining an Autophagy Inhibitor, MPTOL145, with Abemaciclib Is a New Therapeutic Strategy in GBM Treatment. Cancers, 2021, 13, 6117.	3.7	4
278	Ginkgolic Acid Inhibits Proliferation and Migration of Glioblastoma Cells by Inducing Cell Cycle Arrest and Apoptosis. Science of Advanced Materials, 2021, 13, 2295-2301.	0.7	5
279	Tomentosin shows anticancer effect on U87 human glioblastoma multiforme cells. MINAR International Journal of Applied Sciences and Technology, 0, , .	0.1	0
280	Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy. Radiation Oncology, 2022, 17, 79.	2.7	3
281	Brain coâ€delivery of firstâ€line chemotherapy drug and epigenetic bromodomain inhibitor for multidimensional enhanced synergistic glioblastoma therapy. Exploration, 2022, 2, .	11.0	40
282	A 2-Gene Signature Related to Interferon-Gamma Predicts Prognosis and Responsiveness to Immune Checkpoint Blockade of Glioma. Frontiers in Medicine, 2022, 9, 846847.	2.6	0
284	Emerging therapies for glioblastoma: current state and future directions. Journal of Experimental and Clinical Cancer Research, 2022, 41, 142.	8.6	103
285	Efficacy and safety of tumor-treating fields in recurrent glioblastoma: a systematic review and meta-analysis. Acta Neurochirurgica, 2022, 164, 1985-1993.	1.7	5
286	SRPX Emerges as a Potential Tumor Marker in the Extracellular Vesicles of Glioblastoma. Cancers, 2022, 14, 1984.	3.7	2
287	Immune Gene Signatures and Immunotypes in Immune Microenvironment Are Associated With Glioma Prognose. Frontiers in Immunology, 2022, 13, 823910.	4.8	2
288	Proline Metabolism in Malignant Gliomas: A Systematic Literature Review. Cancers, 2022, 14, 2030.	3.7	11
306	ZNF117 regulates glioblastoma stem cell differentiation towards oligodendroglial lineage. Nature Communications, 2022, 13, 2196.	12.8	9
307	Quality of life in patients with glioblastoma and their relatives. Acta Neurologica Scandinavica, 2022, 146, 82-91.	2.1	10
308	The combination of tumor treating fields and hyperthermia has synergistic therapeutic effects in glioblastoma cells by downregulating STAT3.. American Journal of Cancer Research, 2022, 12, 1423-1432.	1.4	0
309	Patient-derived organoids as a model for tumor research. Progress in Molecular Biology and Translational Science, 2022, , 259-326.	1.7	2

#	ARTICLE	IF	CITATIONS
310	Synthetic MRI improves radiomics-based glioblastoma survival prediction. <i>NMR in Biomedicine</i> , 2022, 35, e4754.	2.8	7
311	Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy. <i>Biomedicines</i> , 2022, 10, 1001.	3.2	7
312	Role of Lysine-specific Demethylase 1 and Its Small Molecule Inhibitors in Glioblastoma Multiforme Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 3062-3085.	1.7	2
313	Cloud computing-enabled IIOT system for neurosurgical simulation using augmented reality data access. <i>Digital Communications and Networks</i> , 2023, 9, 347-357.	5.0	3
314	PATZ1 Induces Apoptosis through PUMA in Glioblastoma. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	1.3	4
315	The meningeal lymphatic vessels and the glymphatic system: Potential therapeutic targets in neurological disorders. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 1364-1382.	4.3	17
316	Genome Instability-Associated Long Non-Coding RNAs Reveal Biomarkers for Glioma Immunotherapy and Prognosis. <i>Frontiers in Genetics</i> , 2022, 13, 850888.	2.3	0
317	Epigenetic Underpinnings of Inflammation: A Key to Unlock the Tumor Microenvironment in Glioblastoma. <i>Frontiers in Immunology</i> , 2022, 13, 869307.	4.8	9
318	Association between microRNAs 10b/21/34a and acute toxicity in glioblastoma patients treated with radiotherapy and temozolomide. <i>Scientific Reports</i> , 2022, 12, 7505.	3.3	4
319	3D bioprinted organ-on-a-chips. <i>Aggregate</i> , 2023, 4, .	9.9	35
320	Nanomedicines Targeting Glioma Stem Cells. <i>ACS Applied Materials &amp; Interfaces</i> , 2023, 15, 158-181.	8.0	13
321	Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome-Conjugated Magnetic Nanoparticles for Glioblastoma Therapy. <i>Advanced Science</i> , 2022, 9, e2105451.	11.2	50
322	Rho family GTPase 1 (RND1), a novel regulator of p53, enhances ferroptosis in glioblastoma. <i>Cell and Bioscience</i> , 2022, 12, 53.	4.8	13
323	Therapeutic Options in Neuro-Oncology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5351.	4.1	8
324	Integrin- $\alpha$ 2 $\beta$ 3 as a Therapeutic Target in Glioblastoma: Back to the Future?. <i>Pharmaceutics</i> , 2022, 14, 1053.	4.5	14
325	Targeted Delivery of DNA Topoisomerase Inhibitor SN38 to Intracranial Tumors of Glioblastoma Using Sub- $\mu$ Ultrafine Iron Oxide Nanoparticles. <i>Advanced Healthcare Materials</i> , 2022, 11, e2102816.	7.6	6
326	Dematin inhibits glioblastoma malignancy through RhoA-mediated CDKs downregulation and cytoskeleton remodeling. <i>Experimental Cell Research</i> , 2022, 417, 113196.	2.6	4
327	Integration of synthetic and natural derivatives revives the therapeutic potential of temozolomide against glioma- an in vitro and in vivo perspective. <i>Life Sciences</i> , 2022, 301, 120609.	4.3	7

#	ARTICLE	IF	CITATIONS
328	Mitochondrial Bioenergetics in Different Pathophysiological Conditions 2.0. International Journal of Molecular Sciences, 2022, 23, 5552.	4.1	1
329	Bone metastasis from glioblastoma: a systematic review. Journal of Neuro-Oncology, 2022, 158, 379-392.	2.9	10
330	The Role of NRF2/KEAP1 Pathway in Glioblastoma: Pharmacological Implications. , 2022, 39, 91.		3
331	TGFBI secreted by tumor-associated macrophages promotes glioblastoma stem cell-driven tumor growth via integrin $\alpha 5$ -Src-Stat3 signaling. Theranostics, 2022, 12, 4221-4236.	10.0	29
332	PTBP1 knockdown promotes neural differentiation of glioblastoma cells through UNC5B receptor. Theranostics, 2022, 12, 3847-3861.	10.0	12
333	Sedoheptulose Kinase SHPK Expression in Glioblastoma: Emerging Role of the Nonoxidative Pentose Phosphate Pathway in Tumor Proliferation. International Journal of Molecular Sciences, 2022, 23, 5978.	4.1	4
334	Recurrent glioblastoma: which treatment? A real-world study from the Neuro-oncology Unit of Regina Elena National Cancer Institute. Neurological Sciences, 0, , .	1.9	0
335	The pH-Responsive Liposomes: The Effect of PEGylation on Release Kinetics and Cellular Uptake in Glioblastoma Cells. Pharmaceutics, 2022, 14, 1125.	4.5	5
336	DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma. Frontiers in Immunology, 2022, 13, .	4.8	6
337	Disruption of $\beta$ -catenin-mediated negative feedback reinforces cAMP-induced neuronal differentiation in glioma stem cells. Cell Death and Disease, 2022, 13, .	6.3	5
338	Targeting interleukin-13 receptor $\alpha 2$ (IL-13R $\alpha 2$ ) for glioblastoma therapy with surface functionalized nanocarriers. Drug Delivery, 2022, 29, 1620-1630.	5.7	1
339	PLD2 Is a Prognostic Marker in Glioblastoma That Modulates the Immune Microenvironment and Tumor Progression. International Journal of Molecular Sciences, 2022, 23, 6037.	4.1	6
340	Simultaneous determination of LY3214996, abemaciclib, and M2 and M20 metabolites in human plasma, cerebrospinal fluid, and brain tumor by LC-MS/MS. Journal of Pharmaceutical Analysis, 2022, 12, 601-609.	5.3	4
341	Low-Intensity Focused Ultrasound Technique in Glioblastoma Multiforme Treatment. Frontiers in Oncology, 0, 12, .	2.8	16
342	Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma. International Journal of Molecular Sciences, 2022, 23, 6312.	4.1	6
343	Advantages of Using 3D Intraoperative Ultrasound and Intraoperative MRI in Glioma Surgery. Frontiers in Oncology, 0, 12, .	2.8	1
344	Meta-analysis on reporting practices as a source of heterogeneity in in vitro cancer research. BMJ Open Science, 2022, 6, .	1.7	1
345	A Network Pharmacological Elucidation of the Systematic Treatment Activities and Mechanisms of the Herbal Drug FDY003 Against Esophageal Cancer. Natural Product Communications, 2022, 17, 1934578X2211053.	0.5	0

#	ARTICLE	IF	CITATIONS
347	Hesperetin ameliorates glioblastoma by inhibiting proliferation, inducing apoptosis, and suppressing metastasis. Translational Cancer Research, 2022, 11, 1781-1794.	1.0	2
348	Effects of Lovastatin on Brain Cancer Cells. Cell Transplantation, 2022, 31, 096368972211029.	2.5	6
349	Weighted Gene Co-Expression Network Analysis (WGCNA) Reveals the Functions of Syndecan-1 to Regulate Immune Infiltration by Influenced T Cells in Glioma. Frontiers in Genetics, 0, 13, .	2.3	3
350	Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives. Military Medical Research, 2022, 9, .	3.4	20
351	The Risk of Heart Disease-Related Death Among Anaplastic Astrocytoma Patients After Chemotherapy: A SEER Population-Based Analysis. Frontiers in Oncology, 0, 12, .	2.8	0
352	Hsp90 induces Acsl4-dependent glioma ferroptosis via dephosphorylating Ser637 at Drp1. Cell Death and Disease, 2022, 13, .	6.3	26
353	S645C Point Mutation Suppresses Degradation of EGFR to Promote Progression of Glioblastoma. Frontiers in Oncology, 0, 12, .	2.8	1
354	Brain Coâ€Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy. Advanced Materials, 2022, 34, .	21.0	54
355	Chaperone protein P4HB predicts temozolomide response and prognosis in malignant glioma. Oncology Letters, 2022, 24, .	1.8	5
356	A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas. Journal of Oncology, 2022, 2022, 1-15.	1.3	1
357	The Unfolded Protein Response Sensor PERK Mediates Stiffness-Dependent Adaptation in Glioblastoma Cells. International Journal of Molecular Sciences, 2022, 23, 6520.	4.1	4
358	Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas. Neuro-Oncology, 2023, 25, 97-107.	1.2	3
359	TWIST1 methylation by SETD6 selectively antagonizes LINC-PINT expression in glioma. Nucleic Acids Research, 2022, 50, 6903-6918.	14.5	8
360	Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future. Frontiers in Oncology, 0, 12, .	2.8	6
361	Iron commensalism of mesenchymal glioblastoma promotes ferroptosis susceptibility upon dopamine treatment. Communications Biology, 2022, 5, .	4.4	5
362	Prognostic Value and Biological Function of Galectins in Malignant Glioma. Frontiers in Oncology, 0, 12, .	2.8	6
363	Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis. Pharmacological Research, 2022, 182, 106316.	7.1	3
364	Glycosylation modification identifies novel molecular phenotypes and prognostic stratifications of glioma. Gene, 2022, 836, 146677.	2.2	0

#	ARTICLE	IF	CITATIONS
365	Oncology and mechanics: Landmark studies and promising clinical applications. <i>Advances in Applied Mechanics</i> , 2022, , 513-571.	2.3	2
366	Converging Mechanisms of Epileptogenesis and Their Insight in Glioblastoma. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	2.9	9
367	The Role of microRNAs in Multidrug Resistance of Glioblastoma. <i>Cancers</i> , 2022, 14, 3217.	3.7	11
368	Glioblastoma Treatment: State-of-the-Art and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7207.	4.1	38
369	Magnetic Resonance Spectroscopic Imaging for Detecting Metabolic Changes in Glioblastoma After Anti-angiogenic Therapy-A Systematic Literature Review. <i>Neuro-Oncology Advances</i> , 0, , .	0.7	0
370	Cancer Stem Cell-Associated Immune Microenvironment in Recurrent Glioblastomas. <i>Cells</i> , 2022, 11, 2054.	4.1	8
371	Cleavage of tropomodulin-3 by asparagine endopeptidase promotes cancer malignancy by actin remodeling and SND1/RhoA signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	5
372	S100A10 Is a New Prognostic Biomarker Related to the Malignant Molecular Features and Immunosuppression Process of Adult Gliomas. <i>World Neurosurgery</i> , 2022, , .	1.3	0
373	The Combination of $^{9}\text{T}$ -Tetrahydrocannabinol and Cannabidiol Suppresses Mitochondrial Respiration of Human Glioblastoma Cells via Downregulation of Specific Respiratory Chain Proteins. <i>Cancers</i> , 2022, 14, 3129.	3.7	13
374	Prostate Apoptosis Response-4 (Par-4): A Novel Target in Pyronaridine-Induced Apoptosis in Glioblastoma (GBM) Cells. <i>Cancers</i> , 2022, 14, 3198.	3.7	5
375	Anti-Survival Effect of SI306 and Its Derivatives on Human Glioblastoma Cells. <i>Pharmaceutics</i> , 2022, 14, 1399.	4.5	3
376	Glioma-neuronal interactions in tumor progression: Mechanism, therapeutic strategies and perspectives (Review). <i>International Journal of Oncology</i> , 2022, 61, .	3.3	9
377	PET/NIR-II fluorescence imaging and image-guided surgery of glioblastoma using a folate receptor $\beta$ -targeted dual-modal nanoprobe. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4325-4337.	6.4	14
378	Blood-Brain Barrier Alterations and Edema Formation in Different Brain Mass Lesions. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	3.7	13
379	Targeting glioblastoma through nano- and micro-particle-mediated immune modulation. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 72, 116913.	3.0	3
380	$\text{JUN}$ activation modulates chromatin accessibility to drive $\text{TNF}\alpha$ -induced mesenchymal transition in glioblastoma. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4602-4612.	3.6	2
381	The E3 ubiquitin ligase HUWE1 acts through the $\text{Myc}\text{-DLL1}\text{-NOTCH1}$ signaling axis to suppress glioblastoma progression. <i>Cancer Communications</i> , 2022, 42, 868-886.	9.2	8
382	Highly Invasive Fluorescent/Bioluminescent Patient-Derived Orthotopic Model of Glioblastoma in Mice. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4

#	ARTICLE	IF	CITATIONS
383	Circular RNA VPS18 Promotes Glioblastoma Progression by Regulating miR-1229-3p/BCAT1 Axis. Neurotoxicity Research, 2022, 40, 1138-1151.	2.7	7
384	Identification of Homoharringtonine as a potent inhibitor of glioblastoma cell proliferation and migration. Translational Research, 2023, 251, 41-53.	5.0	2
385	Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1 $\alpha$ expression. Experimental Cell Research, 2022, 418, 113277.	2.6	4
386	LncRNA-FAM66C Was Identified as a Key Regulator for Modulating Tumor Microenvironment and Hypoxia-Related Pathways in Glioblastoma. Frontiers in Public Health, 0, 10, .	2.7	2
387	Thermomagnetic Resonance Effect of the Extremely Low Frequency Electromagnetic Field on Three-Dimensional Cancer Models. International Journal of Molecular Sciences, 2022, 23, 7955.	4.1	2
388	The Signaling Pathways Controlling the Efficacy of Glioblastoma Therapy. , 2022, 14, 62-70.		3
389	Potential targets and treatments affect oxidative stress in gliomas: An overview of molecular mechanisms. Frontiers in Pharmacology, 0, 13, .	3.5	5
390	Simple approach for the histomolecular diagnosis of central nervous system gliomas based on 2021 World Health Organization Classification. World Journal of Clinical Oncology, 2022, 13, 567-576.	2.3	6
391	A Video Data Based Transfer Learning Approach forÂClassification ofÂMGMT Status inÂBrain Tumor MR Images. Lecture Notes in Computer Science, 2022, , 306-314.	1.3	0
392	Development of a Novel Prognostic Model of Glioblastoma Based on m6A-Associated Immune Genes and Identification of a New Biomarker. Frontiers in Oncology, 0, 12, .	2.8	3
393	Protocadherin Gamma C3 (PCDHGC3) Is Strongly Expressed in Glioblastoma and Its High Expression Is Associated with Longer Progression-Free Survival of Patients. International Journal of Molecular Sciences, 2022, 23, 8101.	4.1	3
394	Cross-platform analysis reveals cellular and molecular landscape of glioblastoma invasion. Neuro-Oncology, 2023, 25, 482-494.	1.2	4
395	Aptamer-Modified Erythrocyte Membrane-Coated pH-Sensitive Nanoparticles for c-Met-Targeted Therapy of Glioblastoma Multiforme. Membranes, 2022, 12, 744.	3.0	3
396	Arsenic Prodrug-Mediated Tumor Microenvironment Modulation Platform for Synergetic Glioblastoma Therapy. ACS Applied Materials & Interfaces, 2022, 14, 36487-36502.	8.0	7
398	Therapeutic potential of inhibiting histone 3 lysine 27 demethylases: a review of the literature. Clinical Epigenetics, 2022, 14, .	4.1	11
399	Fluids and flows in brain cancer and neurological disorders. WIREs Mechanisms of Disease, 2023, 15, .	3.3	3
400	Full-course resection control strategy in glioma surgery using both intraoperative ultrasound and intraoperative MRI. Frontiers in Oncology, 0, 12, .	2.8	2
401	PLVAP is associated with glioma-associated malignant processes and immunosuppressive cell infiltration as a promising marker for prognosis. Heliyon, 2022, 8, e10298.	3.2	2

#	ARTICLE	IF	CITATIONS
402	Matricellular protein tenascin C: Implications in glioma progression, gliomagenesis, and treatment. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
403	CD93 is Associated with Glioma-related Malignant Processes and Immunosuppressive Cell Infiltration as an Inspiring Biomarker of Survivance. <i>Journal of Molecular Neuroscience</i> , 2022, 72, 2106-2124.	2.3	4
405	NIR-II absorptive dithienopyrrole-thiadiazolobenzotriazole conjugated polymer for photoacoustic imaging-guided glioblastoma multiforme photothermal therapy. <i>Acta Biomaterialia</i> , 2022, 152, 546-561.	8.3	7
406	Targeting HOTAIRM1 ameliorates glioblastoma by disrupting mitochondrial oxidative phosphorylation and serine metabolism. <i>IScience</i> , 2022, 25, 104823.	4.1	3
407	Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands. <i>Nature Communications</i> , 2022, 13, .	12.8	18
408	STUB1-SMYD2 Axis Regulates Drug Resistance in Glioma cells. <i>Journal of Molecular Neuroscience</i> , 2022, 72, 2030-2044.	2.3	5
409	MiR-33a targets FOSL1 and EN2 as a clinical prognostic marker for sarcopenia by glioma. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	2
410	Quaking but not parkin is the major tumor suppressor in 6q deleted region in glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	2
411	The molecular mechanisms of ferroptosis and its role in glioma progression and treatment. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
412	Targeted Delivery of Chemo-sonodynamic Therapy via Brain Targeting, Glutathione-Consumable Polymeric Nanoparticles for Effective Brain Cancer Treatment. <i>Advanced Science</i> , 2022, 9, .	11.2	16
413	Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, 383, 91-102.	2.5	5
414	Neurotransmitters: Potential Targets in Glioblastoma. <i>Cancers</i> , 2022, 14, 3970.	3.7	8
415	MicroRNA delivery systems in glioma therapy and perspectives: A systematic review. <i>Journal of Controlled Release</i> , 2022, 349, 712-730.	9.9	7
416	Exploring the relationship between age and prognosis in glioma: rethinking current age stratification. <i>BMC Neurology</i> , 2022, 22, .	1.8	8
417	A biodegradable nanocapsule for through-skull NIR-II fluorescence imaging/magnetic resonance imaging and selectively enhanced radio-chemotherapy for orthotopic glioma. <i>Nano Today</i> , 2022, 46, 101619.	11.9	13
418	Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme. <i>Journal of Controlled Release</i> , 2022, 350, 494-513.	9.9	12
419	Downregulation of exosomal MHC-I promotes glioma cells escaping from systemic immunosurveillance. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 46, 102605.	3.3	5
420	Harmine inhibits proliferation and migration of glioblastoma via ERK signalling. <i>Process Biochemistry</i> , 2022, 122, 356-362.	3.7	1



#	ARTICLE	IF	CITATIONS
421	Epigenetics, Stem Cells, Cellular Differentiation, and Associated Neurological Disorders and Brain Cancer. , 2023, , 381-401.		0
422	The Role of Mixed Lineage Kinase 3 (MLK3) in Cancers. SSRN Electronic Journal, 0, , .	0.4	0
423	The N <sup>6</sup> -methyladenosine-mediated lncRNA WEE2-AS1 promotes glioblastoma progression by stabilizing RPN2. Theranostics, 2022, 12, 6363-6379.	10.0	10
424	Targeting extracellular matrix remodeling sensitizes glioblastoma to ionizing radiation. Neuro-Oncology Advances, 2022, 4, .	0.7	1
425	Modern advances in molecular and cellular biology in the treatment of glioblastoma. Onkologiya Zhurnal Imeni P A Gertsena, 2022, 11, 66.	0.2	0
426	Polyphenolic Acetates as Potential Therapeutics and Adjuvant in Radiotherapy of Cancer. , 2022, , 799-815.		0
427	PDA-PEG-Ce6-Mn Multifunctional Nanoparticles for Magnetic Resonance Images-Guided Photo-Dynamic/Photo-Thermal Therapy. Journal of Biomedical Nanotechnology, 2022, 18, 1405-1412.	1.1	0
428	VRK1 as a synthetic lethal target in VRK2 promoterâ€“methylated cancers of the nervous system. JCI Insight, 2022, 7, .	5.0	10
429	Prognosis and Clinical features Analysis of EMT-related Signature and Tumor Immune Microenvironment in Glioma. Journal of Medical Biochemistry, 0, , .	1.7	0
430	Glioblastoma: an organ-confined disease?. Translational Cancer Research, 2022, 11, 2473-2476.	1.0	0
431	Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide. Biomedicines, 2022, 10, 2145.	3.2	2
432	Radiated glioblastoma cell-derived exosomal circ_0012381 induce M2 polarization of microglia to promote the growth of glioblastoma by CCL2/CCR2 axis. Journal of Translational Medicine, 2022, 20, .	4.4	14
433	Chrysomycin A Inhibits the Proliferation, Migration and Invasion of U251 and U87-MG Glioblastoma Cells to Exert Its Anti-Cancer Effects. Molecules, 2022, 27, 6148.	3.8	7
434	Circular RNA-regulated autophagy is involved in cancer progression. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	4
435	Galangin (GLN) Promotes Temozolomide-Induced Apoptosis in Glioma Cells. Biology Bulletin, 2022, 49, 580-587.	0.5	2
436	Sequence-structure functional implications and molecular simulation of high deleterious nonsynonymous substitutions in IDH1 revealed the mechanism of drug resistance in glioma. Frontiers in Pharmacology, 0, 13, .	3.5	5
437	The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations. Nature Communications, 2022, 13, .	12.8	7
438	TRAF4 Promotes the Proliferation of Glioblastoma by Stabilizing SETDB1 to Activate the AKT Pathway. International Journal of Molecular Sciences, 2022, 23, 10161.	4.1	4



#	ARTICLE	IF	CITATIONS
439	Recent developments in the significant effect of mRNA modification (M6A) in glioblastoma and esophageal cancer. <i>Scientific African</i> , 2022, 17, e01347.	1.5	0
440	Integrated genomic, transcriptomic, and epigenetic analyses identify a leukotriene synthesis-related M2 macrophage gene signature that predicts prognosis and treatment vulnerability in gliomas. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
441	Drug delivery in glioblastoma therapy: a review on nanoparticles targeting MGMT-mediated resistance. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 1397-1415.	5.0	5
442	Pathophysiological roles of integrins in gliomas from the perspective of glioma stem cells. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	7
443	Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
444	The impediments of cancer stem cells and an exploration into the nanomedical solutions for glioblastoma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, .	1.7	1
445	Immunogenic cell death related risk model to delineate ferroptosis pathway and predict immunotherapy response of patients with GBM. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
446	Global research trends and hotspots on glioma stem cells. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
447	An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment. <i>Cancer Communications</i> , 2022, 42, 1083-1111.	9.2	32
448	Immunoglobulin-like transcript 2 blockade restores antitumor immune responses in glioblastoma. <i>Cancer Science</i> , 2023, 114, 48-62.	3.9	4
449	The therapeutic effect of an autologous and allogenic mixed glioma cell lysate vaccine in a rat model. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
450	The Chromatin-Oxygen Sensor Gene KDM5C Associates with Novel Hypoxia-Related Signatures in Glioblastoma Multiforme. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10250.	4.1	3
451	A Biomimetic Nanomedicine Targets Orthotopic Glioblastoma by Combinatorial Co-Delivery of Temozolomide and a Methylguanine-DNA Methyltransferase Inhibitor. <i>Advanced Therapeutics</i> , 0, , 2200095.	3.2	1
452	Identification of thioredoxin domain containing family members' expression pattern and prognostic value in diffuse gliomas via in silico analysis. <i>Cancer Medicine</i> , 2023, 12, 3830-3844.	2.8	4
453	Predicting Survival in Patients with Brain Tumors: Current State-of-the-Art of AI Methods Applied to MRI. <i>Diagnostics</i> , 2022, 12, 2125.	2.6	5
454	The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma. <i>Biomedicines</i> , 2022, 10, 2292.	3.2	6
455	Current and promising treatment strategies in glioma. <i>Reviews in the Neurosciences</i> , 2022, .	2.9	3
457	Micro-Nanocarriers Based Drug Delivery Technology for Blood-Brain Barrier Crossing and Brain Tumor Targeting Therapy. <i>Small</i> , 2022, 18, .	10.0	23

#	ARTICLE	IF	CITATIONS
458	Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
459	Gene therapy using genomeâ€edited <scp>iPS</scp> cells for targeting malignant glioma. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	7.1	3
460	CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. <i>Molecular Therapy</i> , 2023, 31, 134-153.	8.2	50
461	The Role of Apparent Diffusion Coefficient Values in Glioblastoma: Differentiating Tumor Progression Versus Treatment-Related Changes. <i>Journal of Computer Assisted Tomography</i> , 2022, 46, 923-928.	0.9	3
462	HOXA1 is a radioresistance marker in multiple cancer types. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
463	Unveiling the Mechanism of the Traditional Korean Medicinal Formula FDY003 on Glioblastoma Through a Computational Network Pharmacology Approach. <i>Natural Product Communications</i> , 2022, 17, 1934578X2211263.	0.5	0
464	Current Understanding of the Neural Stem Cell Niches. <i>Cells</i> , 2022, 11, 3002.	4.1	16
465	Identification of core genes as potential biomarkers for predicting progression and prognosis in glioblastoma. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	1
466	Safety of Inhomogeneous Dose Distribution IMRT for High-Grade Glioma Reirradiation: A Prospective Phase I/II Trial (GLIORAD TRIAL). <i>Cancers</i> , 2022, 14, 4604.	3.7	3
467	Metabolic-imaging of human glioblastoma live tumors: A new precision-medicine approach to predict tumor treatment response early. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	14
468	Microfibrillar-associated protein 2 is a prognostic marker that correlates with the immune microenvironment in glioma. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	1
469	Non-coding RNAs: Key players in T cell exhaustion. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
470	Nonviral nanoparticle gene delivery into the <scp>CNS</scp> for neurological disorders and brain cancer applications. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 0, , .	6.1	4
471	Integrative genomic analysis facilitates precision strategies for glioblastoma treatment. <i>IScience</i> , 2022, 25, 105276.	4.1	0
472	A Composite Bioinformatic Analysis to Explore Endoplasmic Reticulum Stress-Related Prognostic Marker and Potential Pathogenic Mechanisms in Glioma by Integrating Multiomics Data. <i>Journal of Oncology</i> , 2022, 2022, 1-28.	1.3	1
473	Brainâ€Targeting Metastatic Tumor Cell Membrane Cloaked Biomimetic Nanomedicines Mediate Potent Chemodynamic and RNAi Combinational Therapy of Glioblastoma. <i>Advanced Functional Materials</i> , 2022, 32, .	14.9	8
474	Chemotherapeutic Protocols for the Treatment of Neurological Cancer. , 2022, , 307-320.		0
475	A hypoxia-dissociable siRNA nanoplatfrom for synergistically enhanced chemo-radiotherapy of glioblastoma. <i>Biomaterials Science</i> , 2022, 10, 6791-6803.	5.4	2

#	ARTICLE	IF	CITATIONS
476	Glioblastoma multiforme: Diagnosis, treatment, and invasion. Journal of Biomedical Research, 2023, 37, 47.	1.6	1
477	The Emerging Roles and Clinical Potential of circSMARCA5 in Cancer. Cells, 2022, 11, 3074.	4.1	4
478	Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center. Journal of Clinical Medicine, 2022, 11, 5855.	2.4	4
479	Ginsenosides Rg1 and CK Control Temozolomide Resistance in Glioblastoma Cells by Modulating Cholesterol Efflux and Lipid Raft Distribution. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-17.	1.2	3
480	Electromotive Enhanced Drug Administration in Oncology: Principles, Evidence, Current and Emerging Applications. Cancers, 2022, 14, 4980.	3.7	1
481	Dynamically Crosslinked Poly(ethylene glycol) Hydrogels Reveal a Critical Role of Viscoelasticity in Modulating Glioblastoma Fates and Drug Responses in 3D. Advanced Healthcare Materials, 2023, 12, .	7.6	8
482	Combination of pre-treatment dynamic [18F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 535-545.	6.4	7
483	Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma. Pharmaceutics, 2022, 14, 2183.	4.5	28
484	Resveratrol Enhances the Radiosensitivity by Inducing DNA Damage and Antitumor Immunity in a Glioblastoma Rat Model under 3T MRI Monitoring. Journal of Oncology, 2022, 2022, 1-13.	1.3	8
485	Phytochemical Screening, and Antibacterial and Antioxidant Activities of Mangifera indica L. Leaves. Horticulturae, 2022, 8, 909.	2.8	4
486	Metabolomic and Lipidomic Profiling of Gliomas—A New Direction in Personalized Therapies. Cancers, 2022, 14, 5041.	3.7	6
487	A review of the impact of FLASH radiotherapy on the central nervous system and glioma. Radiation Medicine and Protection, 2022, 3, 208-212.	0.8	0
488	Identification of a Fibroblast-Related Prognostic Model in Glioma Based on Bioinformatics Methods. Biomolecules, 2022, 12, 1598.	4.0	9
489	New Directions in the Therapy of Glioblastoma. Cancers, 2022, 14, 5377.	3.7	23
490	Molecular profiling identifies distinct subtypes across TP53 mutant tumors. JCI Insight, 2022, 7, .	5.0	3
491	Nanoparticles for Glioblastoma Treatment. IFMBE Proceedings, 2023, , 656-664.	0.3	0
493	Editorial comment: Radiogenomics of glioblastoma: shifting the focus from tumor cells to immune microenvironment. European Radiology, 0, , .	4.5	0
494	Simulated MRI Artifacts: Testing Machine Learning Failure Modes. BME Frontiers, 2022, 2022, .	4.5	1

#	ARTICLE	IF	CITATIONS
495	Brain-targeted antigen-generating nanoparticles improve glioblastoma prognosis. Journal of Controlled Release, 2022, 352, 399-410.	9.9	7
496	Discovery of novel analogs of KHS101 as transforming acidic coiled coil containing protein 3 (TACC3) inhibitors for the treatment of glioblastoma. European Journal of Medicinal Chemistry, 2022, 244, 114874.	5.5	1
497	Multifunctional PVCL nanogels enable magnetic resonance imaging and immunostimulated radiotherapy of orthotopic glioblastoma. Chemical Engineering Journal, 2023, 453, 139634.	12.7	3
498	Commentary: Laser Interstitial Thermal Therapy for First-Line Treatment of Surgically Accessible Recurrent Glioblastoma: Outcomes Compared With a Surgical Cohort. Neurosurgery, 2022, 91, e160-e163.	1.1	0
499	The role of RNA modification in the generation of acquired drug resistance in glioma. Frontiers in Genetics, 0, 13, .	2.3	1
500	Outcome and characteristics of patients with adult grade 4 diffuse gliomas changing sites of treatment. Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	0
501	Mechanism of exosomes in the tumor microenvironment in the abscopal effect (Review). International Journal of Oncology, 2022, 62, .	3.3	1
502	Near infrared-activatable biomimetic nanogels enabling deep tumor drug penetration inhibit orthotopic glioblastoma. Nature Communications, 2022, 13, .	12.8	24
503	2-Deoxyglucose, an Inhibitor of Glycolysis, Enhances the Oncolytic Effect of Cocksackievirus. Cancers, 2022, 14, 5611.	3.7	5
504	Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011â€“2017): a multicenter retrospective study from CGGA. Cancer Biology and Medicine, 2022, 19, 1460-1476.	3.0	17
505	Fully automated radiomics-based machine learning models for multiclass classification of single brain tumors: Glioblastoma, lymphoma, and metastasis. Journal of Neuroradiology, 2023, 50, 388-395.	1.1	3
506	Melanin-like nanoparticles: advances in surface modification and tumour photothermal therapy. Journal of Nanobiotechnology, 2022, 20, .	9.1	17
507	Hypoxia Enhances Glioma Resistance to Sulfasalazine-Induced Ferroptosis by Upregulating SLC7A11 via PI3K/AKT/HIF-1 $\alpha$ Axis. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-22.	4.0	18
509	Central nervous system tumors. Advances in Magnetic Resonance Technology and Applications, 2023, , 211-235.	0.1	0
510	The RNA-binding protein CSTF2 regulates BAD to inhibit apoptosis in glioblastoma. International Journal of Biological Macromolecules, 2023, 226, 915-926.	7.5	2
511	An integrative non-invasive malignant brain tumors classification and Ki-67 labeling index prediction pipeline with radiomics approach. European Journal of Radiology, 2023, 158, 110639.	2.6	6
512	Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma. Cancer Letters, 2023, 554, 216033.	7.2	8
513	Molecular markers of neuro-oncogenesis in patients with glioblastoma. Zhurnal Voprosy Neirokhirurgii Imeni N N Burdenko, 2022, 86, 99.	0.2	2

#	ARTICLE	IF	CITATIONS
514	Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated <i>MGMT</i> promoter. <i>Epigenomics</i> , 2022, 14, 1233-1247.	2.1	1
515	Photodynamic Opening of the Blood–Brain Barrier and the Meningeal Lymphatic System: The New Niche in Immunotherapy for Brain Tumors. <i>Pharmaceutics</i> , 2022, 14, 2612.	4.5	12
516	The Role of CD4+ T Cells in the Immunotherapy of Brain Disease by Secreting Different Cytokines. <i>Journal of NeuroImmune Pharmacology</i> , 2022, 17, 409-422.	4.1	4
517	Upregulated FKBP1A Suppresses Glioblastoma Cell Growth via Apoptosis Pathway. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14935.	4.1	2
518	Exploring the Physical and Biological Aspects of BNCT with a Carboranyl-methylbenzo[b]acridone Compound in U87 Glioblastoma Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14929.	4.1	1
519	A Review of the Role of Stereotactic Radiosurgery and Immunotherapy in the Management of Primary Central Nervous System Tumors. <i>Biomedicines</i> , 2022, 10, 2977.	3.2	2
520	Diagnostic performance of <i>perfusion-weighted</i> imaging combined with serum <i>MMP-2</i> and <i>MMP-9</i> levels in tumor recurrence after postoperative concomitant chemoradiotherapy of glioblastoma. <i>Journal of Clinical Ultrasound</i> , 2023, 51, 563-570.	0.8	1
521	Inhibition of MZF1/c-MYC Axis by Cantharidin Impairs Cell Proliferation in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14727.	4.1	3
522	Artificial intelligence in cancer imaging for diagnosis and evaluation of treatment response. , 2022, 1, .		0
524	Meta-Analysis of RNA-Seq Datasets Identifies Novel Players in Glioblastoma. <i>Cancers</i> , 2022, 14, 5788.	3.7	0
525	Estimation of Survival in Patients with Glioblastoma Using an Online Calculator at a Tertiary-Level Hospital in Mexico. <i>Cureus</i> , 2022, , .	0.5	0
526	Assessment and prediction of glioblastoma therapy response: challenges and opportunities. <i>Brain</i> , 2023, 146, 1281-1298.	7.6	3
528	Differentiation of Perilesional Edema in Glioblastomas and Brain Metastases: Comparison of Diffusion Tensor Imaging, Neurite Orientation Dispersion and Density Imaging and Diffusion Microstructure Imaging. <i>Cancers</i> , 2023, 15, 129.	3.7	3
529	<i>Porphyromonas gingivalis</i> -Derived Lipopolysaccharide Promotes Glioma Cell Proliferation and Migration via Activating Akt Signaling Pathways. <i>Cells</i> , 2022, 11, 4088.	4.1	1
530	Roles of RNA-binding proteins in neurological disorders, COVID-19, and cancer. <i>Human Cell</i> , 2023, 36, 493-514.	2.7	2
531	LncRNA <i>SPRY4-IT1</i> facilitates cell proliferation and angiogenesis of glioma via the <i>miR-101-3p/EZH2/VEGFA</i> signaling axis. <i>Cancer Medicine</i> , 2023, 12, 7309-7326.	2.8	2
532	Emerging Materials, Wearables, and Diagnostic Advancements in Therapeutic Treatment of Brain Diseases. <i>Biosensors</i> , 2022, 12, 1176.	4.7	1
533	Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors. <i>Diagnostics</i> , 2022, 12, 3120.	2.6	2

#	ARTICLE	IF	CITATIONS
534	CACA guidelines for holistic integrative management of glioma. , 2022, 1, .		0
535	Pan-cancer analysis of ASB3 and the potential clinical implications for immune microenvironment of glioblastoma multiforme. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
536	DeepEOR: automated perioperative volumetric assessment of variable grade gliomas using deep learning. <i>Acta Neurochirurgica</i> , 2023, 165, 555-566.	1.7	1
537	Xanthatin suppresses proliferation and tumorigenicity of glioma cells through autophagy inhibition via activation of the PI3Kâ€‘Aktâ€‘mTOR pathway. <i>Pharmacology Research and Perspectives</i> , 2023, 11, .	2.4	5
538	Transformable â€‘Tubulin Trapsâ€‘Interfere with Mitochondrial Autophagy and Promote the Elimination of Glioblastoma. <i>Advanced Functional Materials</i> , 2023, 33, .	14.9	1
539	Assessment of immunotherapy response in intracranial malignancy using semi-automatic segmentation on magnetic resonance images. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
540	The Regulatory Mechanisms and Clinical Significance of Lnc SNHG4 in Cancer. <i>Current Pharmaceutical Design</i> , 2022, 28, 3563-3571.	1.9	2
541	Focused Ultrasound Enhances Brain Delivery of Sorafenib Nanoparticles. <i>Advanced NanoBiomed Research</i> , 0, , 2200142.	3.6	0
542	A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma. <i>Medicina (Lithuania)</i> , 2023, 59, 23.	2.0	1
543	ALKBH5 promotes PD-L1-mediated immune escape through m6A modification of ZDHHC3 in glioma. <i>Cell Death Discovery</i> , 2022, 8, .	4.7	15
544	Mapping the functional expression of auxiliary subunits of KCa1.1 in glioblastoma. <i>Scientific Reports</i> , 2022, 12, .	3.3	0
545	Biomimetic calcium carbonate nanoparticles delivered IL-12 mRNA for targeted glioblastoma sono-immunotherapy by ultrasound-induced necroptosis. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	9.1	17
546	Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
548	NF-Î‘B Inhibitor Myrislignan Induces Ferroptosis of Glioblastoma Cells via Regulating Epithelial-Mesenchymal Transformation in a Slug-Dependent Manner. <i>Oxidative Medicine and Cellular Longevity</i> , 2023, 2023, 1-16.	4.0	5
549	AI-based MRI auto-segmentation of brain tumor in rodents, a multicenter study. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	5.2	3
550	The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest. <i>Cell Death and Disease</i> , 2023, 14, .	6.3	14
551	Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrowâ€‘Derived Macrophages. <i>Cancer Research</i> , 2023, 83, 771-785.	0.9	6
552	Identification of therapeutic targets and prognostic biomarkers among frizzled family genes in glioma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	1

#	ARTICLE	IF	CITATIONS
554	CASP4 can be a diagnostic biomarker and correlated with immune infiltrates in gliomas. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
555	Exploring the prognostic value of HK3 and its association with immune infiltration in glioblastoma multiforme. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	0
556	Resting state network mapping in individuals using deep learning. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	3
557	The prognostic significance of tumor-associated neutrophils and circulating neutrophils in glioblastoma (WHO CNS5 classification). <i>BMC Cancer</i> , 2023, 23, .	2.6	3
558	Biomaterial-based in vitro 3D modeling of glioblastoma multiforme. , 2023, 1, 177-194.		2
559	The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	2
560	Identification of a robust scoring system based on metabolic genes followed by in-depth validation of ATP1A3 in glioma. <i>Life Sciences</i> , 2023, 315, 121377.	4.3	1
561	Multiparametric Magnetic Resonance Imaging Correlates of Isocitrate Dehydrogenase Mutation in WHO high-Grade Astrocytomas. <i>Journal of Personalized Medicine</i> , 2023, 13, 72.	2.5	0
562	The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma. <i>Drug Delivery</i> , 2023, 30, 1-13.	5.7	4
563	Advances in targeting of miRâ€™10â€™associated lncRNAs/circRNAs for the management of cancer (Review). <i>Oncology Letters</i> , 2023, 25, .	1.8	1
564	The PTEN-associated immune prognostic signature reveals the landscape of the tumor microenvironment in glioblastoma. <i>Journal of Neuroimmunology</i> , 2023, 376, 578034.	2.3	1
565	Non-Association of Driver Alterations in PTEN with Differential Gene Expression and Gene Methylation in IDH1 Wildtype Glioblastomas. <i>Brain Sciences</i> , 2023, 13, 186.	2.3	0
566	Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma. <i>Cancers</i> , 2023, 15, 830.	3.7	8
567	The efficacy of targeted therapy combined with radiotherapy and temozolomide-based chemotherapy in the treatment of glioma: A systemic review and meta-analysis of phase II/III randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
568	Long Non-coding RNA KTN1-AS1 Targets miR-505 to Promote Glioblastoma Progression. <i>Behavioural Neurology</i> , 2023, 2023, 1-11.	2.1	1
569	The Role of Hypoxia in Brain Tumor Immune Responses. <i>Brain Tumor Research and Treatment</i> , 2023, 11, 39.	1.0	1
570	Recent Advances on Surface-Modified GBM Targeted Nanoparticles: Targeting Strategies and Surface Characterization. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2496.	4.1	3
571	A novel cuproptosis-related lncRNA signature: Prognostic and therapeutic value for low grade glioma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4



#	ARTICLE	IF	CITATIONS
572	Eighteen yearsâ€™ experience with tumor treating fields in the treatment of newly diagnosed glioblastoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
573	Harnessing Folate-Functionalized Nasal Delivery of Doxâ€™Erlo-Loaded Biopolymeric Nanoparticles in Cancer Treatment: Development, Optimization, Characterization, and Biodistribution Analysis. <i>Pharmaceutics</i> , 2023, 16, 207.	3.8	8
574	Honokiol-Loaded Nanoemulsion for Glioblastoma Treatment: Statistical Optimization, Physicochemical Characterization, and an In Vitro Toxicity Assay. <i>Pharmaceutics</i> , 2023, 15, 448.	4.5	9
575	Small Structural Differences Govern the Carbonic Anhydrase II Inhibition Activity of Cytotoxic Triterpene Acetazolamide Conjugates. <i>Molecules</i> , 2023, 28, 1009.	3.8	5
576	Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report. <i>Biomedicines</i> , 2023, 11, 311.	3.2	3
577	Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
579	Impact of Extended Adjuvant Temozolamide Beyond 6 Months in the Management of Glioblastoma Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2023, 46, 101-106.	1.3	2
580	An Integrated Monte Carlo Model for Heterogeneous Glioblastoma Treated with Boron Neutron Capture Therapy. <i>Cancers</i> , 2023, 15, 1550.	3.7	1
581	The brain-penetrant cell-cycle inhibitor p28 sensitizes brain metastases to DNA-damaging agents. <i>Neuro-Oncology Advances</i> , 2023, 5, .	0.7	2
582	Impact of age and gender on glioblastoma onset, progression, and management. <i>Mechanisms of Ageing and Development</i> , 2023, 211, 111801.	4.6	6
583	Live-attenuated Japanese encephalitis virus inhibits glioblastoma growth and elicits potent antitumor immunity. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
584	Advanced Radio Frequency Applicators for Thermal Magnetic Resonance Theranostics of Brain Tumors. <i>Cancers</i> , 2023, 15, 2303.	3.7	2
585	CD73 in glioblastoma: Where are we now and what are the future directions?. <i>Immunology Letters</i> , 2023, 256-257, 20-27.	2.5	1
586	Nifuroxazide inhibits the growth of glioblastoma and promotes the infiltration of CD8 T cells to enhance antitumour immunity. <i>International Immunopharmacology</i> , 2023, 118, 109987.	3.8	3
587	Resveratrol inhibits glioblastoma cells and chemoresistance progression through blockade P-glycoprotein and targeting AKT/PTEN signaling pathway. <i>Chemico-Biological Interactions</i> , 2023, 376, 110409.	4.0	4
588	Knock-down of PGM1 inhibits cell viability, glycolysis, and oxidative phosphorylation in glioma under low glucose condition via the Myc signaling pathway. <i>Biochemical and Biophysical Research Communications</i> , 2023, 656, 38-45.	2.1	3
589	BZW1 as an oncogene is associated with patient prognosis and the immune microenvironment in glioma. <i>Genomics</i> , 2023, 115, 110602.	2.9	0
590	The clinical progression of patients with glioblastoma. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2023, 32, 101756.	0.3	2



#	ARTICLE	IF	CITATIONS
591	Engineered M13 phage as a novel therapeutic bionanomaterial for clinical applications: From tissue regeneration to cancer therapy. <i>Materials Today Bio</i> , 2023, 20, 100612.	5.5	9
592	A clinical evaluation of cystic features in patients with newly diagnosed glioblastoma with IDH-wildtype. <i>Clinical Neurology and Neurosurgery</i> , 2023, 228, 107708.	1.4	0
593	From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer. <i>Advanced Drug Delivery Reviews</i> , 2023, 196, 114777.	13.7	8
594	Emerging ultrasonic bioelectronics for personalized healthcare. <i>Progress in Materials Science</i> , 2023, 136, 101110.	32.8	10
595	Diabetes Mellitus Management in the Context of Cranial Tumors. , 2023, 1, 29-39.		1
596	Glioblastoma Spheroid Invasion through Soft, Brain-Like Matrices Depends on Hyaluronic Acid-CD44 Interactions. <i>Advanced Healthcare Materials</i> , 2023, 12, .	7.6	6
597	Efficacy and Safety of Bevacizumab for Treating Glioblastoma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials. <i>Cancer Investigation</i> , 2023, 41, 305-317.	1.3	1
598	Noninvasively evaluating the grade and IDH mutation status of gliomas by using mono-exponential, bi-exponential diffusion-weighted imaging and three-dimensional pseudo-continuous arterial spin labeling. <i>European Journal of Radiology</i> , 2023, 160, 110721.	2.6	0
600	Polyhedral Oligomeric Silsesquioxane-Based Nanoparticles for Efficient Chemotherapy of Glioblastoma. <i>Small</i> , 2023, 19, .	10.0	6
601	Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy. <i>Pharmaceuticals</i> , 2023, 16, 227.	3.8	8
602	T1-Weighted Contrast Enhancement, Apparent Diffusion Coefficient, and Cerebral-Blood-Volume Changes after Glioblastoma Resection: MRI within 48 Hours vs. beyond 48 Hours. <i>Tomography</i> , 2023, 9, 342-351.	1.8	2
603	Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. <i>PLoS ONE</i> , 2023, 18, e0281166.	2.5	5
604	A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma. <i>Tomography</i> , 2023, 9, 362-374.	1.8	1
605	Shallow- and Deep-Water Ophiura Species Produce a Panel of Chlorin Compounds with Potent Photodynamic Anticancer Activities. <i>Antioxidants</i> , 2023, 12, 386.	5.1	1
606	The impact of brain lesions on health-related quality of life in patients with WHO CNS grade 3 or 4 glioma: a lesion-function and resting-state fMRI analysis. <i>Journal of Neuro-Oncology</i> , 2023, 161, 643-654.	2.9	1
608	Charged particle therapy for high-grade gliomas in adults: a systematic review. <i>Radiation Oncology</i> , 2023, 18, .	2.7	1
609	Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies. <i>Viruses</i> , 2023, 15, 547.	3.3	15
610	PLK1 inhibition promotes apoptosis and DNA damage in glioma stem cells by regulating the nuclear translocation of YBX1. <i>Cell Death Discovery</i> , 2023, 9, .	4.7	6

#	ARTICLE	IF	CITATIONS
611	A nitric-oxide driven chemotactic nanomotor for enhanced immunotherapy of glioblastoma. Nature Communications, 2023, 14, .	12.8	27
613	Non-invasive PTEN mRNA brain delivery effectively mitigates growth of orthotopic glioblastoma. Nano Today, 2023, 49, 101790.	11.9	12
614	Supratotal Resection of Glioblastoma: Better Survival Outcome than Gross Total Resection. Journal of Personalized Medicine, 2023, 13, 383.	2.5	2
615	Spatial transcriptomics reveals niche-specific enrichment and vulnerabilities of radial glial stem-like cells in malignant gliomas. Nature Communications, 2023, 14, .	12.8	23
616	Extrication of Survival Associated Genes of Glioblastoma Multiforme Patient through Statistical Modeling. , 2022, , .		1
617	SERPINF1 Mediates Tumor Progression and Stemness in Glioma. Genes, 2023, 14, 580.	2.4	2
618	Metabolic Barriers to Glioblastoma Immunotherapy. Cancers, 2023, 15, 1519.	3.7	2
619	LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells. Cancer Immunology, Immunotherapy, 2023, 72, 2179-2193.	4.2	4
620	A new immune checkpoint-associated nine-gene signature for prognostic prediction of glioblastoma. Medicine (United States), 2023, 102, e33150.	1.0	0
621	Prediction of IDH1 Gene expression in Glioblastoma Using Machine Learning Techniques. , 2022, , .		0
622	Opportunities and challenges related to ferroptosis in glioma and neuroblastoma. Frontiers in Oncology, 0, 13, .	2.8	3
624	Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas. International Journal of Molecular Sciences, 2023, 24, 5016.	4.1	3
625	Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials. ACS Pharmacology and Translational Science, 2023, 6, 447-518.	4.9	28
626	Co-delivery of paclitaxel and etoposide prodrug by human serum albumin and PLGA nanoparticles: synergistic cytotoxicity in brain tumour cells. Journal of Microencapsulation, 2023, 40, 246-262.	2.8	3
627	Prognostic role of the pretreatment systemic immune-inflammation index in patients with glioma: A meta-analysis. Frontiers in Neurology, 0, 14, .	2.4	6
628	Metformin and simvastatin exert additive antitumour effects in glioblastoma via senescence-state: clinical and translational evidence. EBioMedicine, 2023, 90, 104484.	6.1	10
629	Design and Computational Analysis of an MMP9 Inhibitor in Hypoxia-Induced Glioblastoma Multiforme. ACS Omega, 2023, 8, 10565-10590.	3.5	1
630	Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma. Pharmaceutics, 2023, 15, 928.	4.5	3

#	ARTICLE	IF	CITATIONS
631	Dimethylation of histone H3 lysine 36 (H3K36me2) as a potential biomarker for glioma diagnosis, grading, and prognosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2023, 82, 412-418.	1.7	1
632	Rab32 promotes glioblastoma migration and invasion via regulation of ERK/Drp1-mediated mitochondrial fission. <i>Cell Death and Disease</i> , 2023, 14, .	6.3	6
633	Dendrimer: An update on recent developments and future opportunities for the brain tumors diagnosis and treatment. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	5
634	Quercetin and Its Nano-Formulations for Brain Tumor Therapy—Current Developments and Future Perspectives for Paediatric Studies. <i>Pharmaceutics</i> , 2023, 15, 963.	4.5	6
635	A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	4
636	Fatostatin induces ferroptosis through inhibition of the AKT/mTORC1/GPX4 signaling pathway in glioblastoma. <i>Cell Death and Disease</i> , 2023, 14, .	6.3	14
637	Exploring Monocytes-Macrophages in Immune Microenvironment of Glioblastoma for the Design of Novel Therapeutic Strategies. <i>Brain Sciences</i> , 2023, 13, 542.	2.3	4
638	Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. <i>Lancet Oncology</i> , The, 2023, 24, e161-e171.	10.7	4
639	Untargeted Metabolomic Characterization of Glioblastoma Intra-Tumor Heterogeneity Using OrbiSIMS. <i>Analytical Chemistry</i> , 2023, 95, 5994-6001.	6.5	2
640	Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM). <i>Cancers</i> , 2023, 15, 2116.	3.7	17
641	Development and validation of a glioma-associated mesenchymal stem cell-related gene prognostic index for predicting prognosis and guiding individualized therapy in glioma. <i>Stem Cell Research and Therapy</i> , 2023, 14, .	5.5	1
642	Potential role of a novel biphenanthrene derivative isolated from <i>Aerides falcata</i> in central nervous system diseases. <i>RSC Advances</i> , 2023, 13, 10757-10767.	3.6	0
644	Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression. <i>Human Genomics</i> , 2023, 17, .	2.9	1
645	Fourier transform infrared spectroscopic marker of glioblastoma obtained from machine learning and changes in the spectra. <i>Photodiagnosis and Photodynamic Therapy</i> , 2023, 42, 103550.	2.6	5
646	MiR-10b-5p Impairs TET2-Mediated Inhibition of PD-L1 Transcription Thus Promoting Immune Evasion and Tumor Progression in Glioblastoma. <i>Tohoku Journal of Experimental Medicine</i> , 2023, 260, 205-214.	1.2	3
647	System analysis based on the migration- and invasion-related gene sets identifies the infiltration-related genes of glioma. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
648	Arrestins: Structure, Function, Physiology, and Pharmacological Perspectives. <i>Pharmacological Reviews</i> , 2023, 75, 854-884.	16.0	15
649	Hsa_circITGA4/ miR-1468/EGFR/ PTEN a Master Regulators Axis in Glioblastoma Development and Progression. <i>Molecular Biotechnology</i> , 2024, 66, 90-101.	2.4	1

#	ARTICLE	IF	CITATIONS
650	LAT1 targeted brain delivery of temozolomide and sorafenib for effective glioma therapy. Nano Research, 2023, 16, 9743-9751.	10.4	2
651	Glioblastoma Microenvironment and Invasiveness: New Insights and Therapeutic Targets. International Journal of Molecular Sciences, 2023, 24, 7047.	4.1	14
652	Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview. Metabolites, 2023, 13, 543.	2.9	2
654	Personalised therapeutic approaches to glioblastoma: A systematic review. Frontiers in Medicine, 0, 10, .	2.6	4
655	CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway. Cell Death and Disease, 2023, 14, .	6.3	6
656	Transglutaminase-Polyethyleneimine Nanoflowers Mediated Cellular Delivery of Anti-miR-210 for Effective Glioblastoma Therapy. ACS Biomaterials Science and Engineering, 2023, 9, 2558-2571.	5.2	1
657	Temozolomide and Lomustine Induce Tissue Factor Expression and Procoagulant Activity in Glioblastoma Cells In Vitro. Cancers, 2023, 15, 2347.	3.7	1
658	Novel tumor necrosis factor-related long non-coding RNAs signature for risk stratification and prognosis in glioblastoma. Frontiers in Neurology, 0, 14, .	2.4	0
659	Fractionated stereotactic re-irradiation for recurrent glioblastoma: A systematic review and meta-analysis. Clinical Neurology and Neurosurgery, 2023, 229, 107728.	1.4	1
660	Current approaches in enhancing TRAIL therapies in glioblastoma. Neuro-Oncology Advances, 2023, 5, .	0.7	1
661	The Promise of Niacin in Neurology. Neurotherapeutics, 2023, 20, 1037-1054.	4.4	2
662	Added value of [18F]FDOPA PET to the management of high-grade glioma patients after their initial treatment: a prospective multicentre study. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 2727-2735.	6.4	1
663	Recruiting T&#x2013;Cells toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co&#x2013;Delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage&#x2013;Membrane&#x2013;Camouflaged Nanovesicles. Advanced Materials, 2023, 35, .	21.0	7
664	A Comprehensive View(COUP D&#x2013;OEIL) of Brain Tumors from Eastern India. World Neurosurgery, 2023, 175, e1237-e1245.	1.3	0
665	A novel gene, TARDBP, and the protein it encodes can predict glioma patient prognosis and establish a prediction model. BMC Neurology, 2023, 23, .	1.8	0
666	Screening and anti&#x2013;glioma activity of <i>Chiloscyllium plagiosum</i> anti&#x2013;human <sc>IL&#x2013;13R&#x2013;2</sc> single&#x2013;domain antibody. Immunology, 0, , .	4.4	1
667	Low-dose pleiotropic radiosensitive nanoformulations for three-pronged radiochemotherapy of hypoxic brain glioblastoma under BOLD/DWI monitoring. Cancer Nanotechnology, 2023, 14, .	3.7	1
668	Functional importance of glucose transporters and chromatin epigenetic factors in Glioblastoma Multiforme (GBM): possible therapeutics. Metabolic Brain Disease, 2023, 38, 1441-1469.	2.9	2

#	ARTICLE	IF	CITATIONS
669	High-frequency irreversible electroporation improves survival and immune cell infiltration in rodents with malignant gliomas. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	4
670	Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment. <i>Cell Communication and Signaling</i> , 2023, 21, .	6.5	8
671	Analysis and validation of aging-related genes in prognosis and immune function of glioblastoma. <i>BMC Medical Genomics</i> , 2023, 16, .	1.5	0
672	Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9075.	4.1	0
673	Ursolic acid nanoparticles for glioblastoma therapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2023, 50, 102684.	3.3	1
674	Redox Homeostasis and Beyond: The Role of Wild-Type Isocitrate Dehydrogenases for the Pathogenesis of Glioblastoma. <i>Antioxidants and Redox Signaling</i> , 0, , .	5.4	1
675	Ace gene insertion/deletion polymorphism is associated with glioblastoma in an Iranian population: a case-control study. <i>Siberian Journal of Oncology</i> , 2023, 22, 85-92.	0.3	1
676	Emerging Nano-immunotherapeutic Approaches to Glioma. <i>Small Structures</i> , 2023, 4, .	12.0	0
677	Meningeal lymphatic vasculature, a general target for glioblastoma therapy?. <i>Fundamental Research</i> , 2023, , .	3.3	0
678	Long-acting therapeutic delivery systems for the treatment of gliomas. <i>Advanced Drug Delivery Reviews</i> , 2023, 197, 114853.	13.7	3
680	Immunosuppressive cells in oncolytic virotherapy for glioma: challenges and solutions. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	3.9	3
681	RYK Gene Expression Associated with Drug Response Variation of Temozolomide and Clinical Outcomes in Glioma Patients. <i>Pharmaceuticals</i> , 2023, 16, 726.	3.8	0
683	Risk factor analysis and nomogram establishment and verification of brain astrocytoma patients based on SEER database. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
685	P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma. <i>Scientific Reports</i> , 2023, 13, .	3.3	4
686	WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models. <i>Neuro-Oncology Advances</i> , 2023, 5, .	0.7	2
687	Chrysomycin A Regulates Proliferation and Apoptosis of Neuroglioma Cells via the Akt/GSK-3 $\beta$ Signaling Pathway In Vivo and In Vitro. <i>Marine Drugs</i> , 2023, 21, 329.	4.6	1
688	Measurement of Patient-Derived Glioblastoma Cell Response to Temozolomide Using Fluorescence Lifetime Imaging of NAD(P)H. <i>Pharmaceuticals</i> , 2023, 16, 796.	3.8	0
689	<sc>SNHG1</sc>, a <sc>KLF4</sc>-upregulated gene, promotes glioma cell survival and tumorigenesis under endoplasmic reticulum stress by upregulating <sc>BIRC3</sc> expression. <i>Journal of Cellular and Molecular Medicine</i> , 2023, 27, 1806-1819.	3.6	1

#	ARTICLE	IF	CITATIONS
690	Theranostic in glioblastoma. , 2023, , 613-630.		0
691	New surgical approaches in glioblastoma. , 2023, , 167-186.		0
692	An efficient reactive oxygen species/reactive nitrogen species generator for dual imaging-guided orthotopic glioblastoma therapy through intrathecal delivery. Nano Today, 2023, 50, 101886.	11.9	2
693	Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme. Metabolic Brain Disease, 0, , .	2.9	1
694	Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma. BioDrugs, 2023, 37, 489-503.	4.6	1
695	Intra-lesion injection of activated Natural Killer (NK) cells in recurrent malignant brain tumors. International Immunopharmacology, 2023, 120, 110345.	3.8	2
696	Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis. Journal of Neuro-Oncology, 0, , .	2.9	0
697	Zinc finger and SCAN domain-containing 18 suppresses the proliferation, self-renewal, and drug resistance of glioblastoma cells. Heliyon, 2023, 9, e17000.	3.2	0
698	Lemur tyrosine kinase 2 has a tumor-inhibition function in human glioblastoma by regulating the RUNX3/Notch pathway. Biochimica Et Biophysica Acta - Molecular Cell Research, 2023, 1870, 119509.	4.1	2
699	Multidisciplinary docking, kinetics and X-ray crystallography studies of baicalein acting as a glycogen phosphorylase inhibitor and determination of itsâ€™ potential against glioblastoma in cellular models. Chemico-Biological Interactions, 2023, 382, 110568.	4.0	2
700	Program and Abstracts. Tissue Engineering - Part A, 2023, 29, 1-1650.	3.1	0
702	Biomedical application of 2D nanomaterials in neuroscience. Journal of Nanobiotechnology, 2023, 21, .	9.1	4
703	Dendritic cell vaccine trials in gliomas: Untangling the lines. Neuro-Oncology, 2023, 25, 1752-1762.	1.2	6
706	InmunopatologÃa del Glioblastoma Multiforme y su importancia en el Ãmbito clÃnico. Revista Ciencias BiomÃdicas (cartagena), 2022, 11, 163-178.	0.0	0
707	Psychosocial interventions for personality and behavior changes in adults with a brain tumor: A scoping review. Neuro-Oncology Practice, 2023, 10, 408-417.	1.6	0
708	Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map. BMC Cancer, 2023, 23, .	2.6	10
709	Integration analysis of single-cell and spatial transcriptomics reveal the cellular heterogeneity landscape in glioblastoma and establish a polygenic risk model. Frontiers in Oncology, 0, 13, .	2.8	2
710	Bio-inspired self-assembled bacteriochlorin nanoparticles for superior visualization and photothermal ablation of tumors. Biomedicine and Pharmacotherapy, 2023, 165, 115014.	5.6	2



#	ARTICLE	IF	CITATIONS
711	Innovative Approach to Isolate and Characterize Glioblastoma Circulating Tumor Cells and Correlation with Tumor Mutational Status. <i>International Journal of Molecular Sciences</i> , 2023, 24, 10147.	4.1	0
712	Dexamethasone Inhibits Heparan Sulfate Biosynthetic System and Decreases Heparan Sulfate Content in Orthotopic Glioblastoma Tumors in Mice. <i>International Journal of Molecular Sciences</i> , 2023, 24, 10243.	4.1	2
713	Epigenetically modified AP-2 $\beta$ by DNA methyltransferase facilitates glioma immune evasion by upregulating PD-L1 expression. <i>Cell Death and Disease</i> , 2023, 14, .	6.3	1
714	Macrophage Membrane-Coated Nanoparticles Sensitize Glioblastoma to Radiation by Suppressing Proneural-Mesenchymal Transformation in Glioma Stem Cells. <i>Advanced Functional Materials</i> , 2023, 33, .	14.9	4
715	Outcomes of HSV-1 encephalitis infection in glioblastoma: An integrated systematic analysis. <i>Microbial Pathogenesis</i> , 2023, 181, 106211.	2.9	1
716	Development and validation of a predictive model in diagnosis and prognosis of primary glioblastoma patients based on Homeobox A family. <i>Discover Oncology</i> , 2023, 14, .	2.1	1
717	Insights into the Role of LncRNAs and miRNAs in Glioma Progression and Their Potential as Novel Therapeutic Targets. <i>Cancers</i> , 2023, 15, 3298.	3.7	2
719	On the origin and development of glioblastoma: multifaceted role of perivascular mesenchymal stromal cells. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	5.2	3
720	Design, synthesis, and biological evaluation of novel spirocyclic compounds as potential anti-glioblastoma agents. <i>European Journal of Medicinal Chemistry</i> , 2023, 258, 115595.	5.5	0
721	Diagnostic and Therapeutic Approaches for Glioblastoma and Neuroblastoma Cancers Using Chlorotoxin Nanoparticles. <i>Cancers</i> , 2023, 15, 3388.	3.7	2
722	Insights into Healthcare Professionals' Perceptions and Attitudes toward Nanotechnological Device Application: What Is the Current Situation in Glioblastoma Research?. <i>Biomedicines</i> , 2023, 11, 1854.	3.2	0
723	MiR-146a-5p deficiency in extracellular vesicles of glioma-associated macrophages promotes epithelial-mesenchymal transition through the NF- $\kappa$ B signaling pathway. <i>Cell Death Discovery</i> , 2023, 9, .	4.7	5
724	Machine learning applications on intratumoral heterogeneity in glioblastoma using single-cell RNA sequencing data. <i>Briefings in Functional Genomics</i> , 0, , .	2.7	0
725	The complementary role of MRI and FET PET in high grade gliomas to differentiate recurrence from radionecrosis. <i>Frontiers in Nuclear Medicine</i> , 0, 3, .	1.2	0
726	Recent Advances in the Treatment of Glioblastoma. <i>Advances in Clinical Medicine</i> , 2023, 13, 6681-6685.	0.0	0
727	Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic. <i>Biomacromolecules</i> , 2023, 24, 2674-2690.	5.4	1
728	Evaluating glioblastoma tumour sphere growth and migration in interaction with astrocytes using 3D collagen-hyaluronic acid hydrogels. <i>Journal of Materials Chemistry B</i> , 2023, 11, 5442-5459.	5.8	2
729	Kaempferol inhibits non-homologous end joining repair via regulating Ku80 stability in glioma cancer. <i>Phytomedicine</i> , 2023, 116, 154876.	5.3	1



#	ARTICLE	IF	CITATIONS
730	Sonodynamic therapy and magnetic resonance-guided focused ultrasound: new therapeutic strategy in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2023, 163, 219-238.	2.9	6
731	Barriers to overcoming immunotherapy resistance in glioblastoma. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	3
732	Complementary roles of EP2 and EP4 receptors in malignant glioma. <i>British Journal of Pharmacology</i> , 2023, 180, 2623-2640.	5.4	4
733	Local Drug Delivery Techniques for Triggering Immunogenic Cell Death. <i>Small Methods</i> , 2023, 7, .	8.6	4
734	Multi-omic integration of <sc>DNA</sc> methylation and gene expression data reveals molecular vulnerabilities in glioblastoma. <i>Molecular Oncology</i> , 2023, 17, 1726-1743.	4.6	0
735	Immunotherapy for Recurrent Gliomaâ€”From Bench to Bedside. <i>Cancers</i> , 2023, 15, 3421.	3.7	1
736	Clinical and molecular analysis of cilia-associated gene signature for prognostic prediction in glioma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
737	In-depth understanding of higher-order genome architecture in orphan cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188948.	7.4	0
738	Glioblastoma research on zebrafish xenograft models: a systematic review. <i>Clinical and Translational Oncology</i> , 2024, 26, 311-325.	2.4	1
739	Photodynamic Therapy for Glioblastoma: Illuminating the Path toward Clinical Applicability. <i>Cancers</i> , 2023, 15, 3427.	3.7	9
740	The prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma. <i>BMC Bioinformatics</i> , 2023, 24, .	2.6	1
741	Gut-Microbiota-Immune-Brain Axis and Brain Glioma: A Well-Established Connection and a Potential Strategy for Precision Oncology. , 2023, , 1-16.		0
742	Tyrphostin A9 attenuates glioblastoma growth by suppressing PYK2/EGFR-ERK signaling pathway. <i>Journal of Neuro-Oncology</i> , 0, , .	2.9	1
743	Risk of stroke-specific mortality after radiotherapy in patients with primary brain tumours. <i>Clinical and Translational Radiation Oncology</i> , 2023, 42, 100658.	1.7	0
744	Nanoparticles Mediated the Diagnosis and Therapy of Glioblastoma: Bypass or Cross the Bloodâ€”Brain Barrier. <i>Small</i> , 2023, 19, .	10.0	3
745	Chronic stress accelerates glioblastoma progression via DRD2/ERK/Î²-catenin axis and Dopamine/ERK/TH positive feedback loop. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	8.6	3
746	Ginsenoside Rg3-engineered exosomes as effective delivery platform for potentiated chemotherapy and photoimmunotherapy of glioblastoma. <i>Chemical Engineering Journal</i> , 2023, 471, 144692.	12.7	3
747	Fucoxanthin triggers ferroptosis in glioblastoma cells by stabilizing the transferrin receptor. , 2023, 40, .		1

#	ARTICLE	IF	CITATIONS
748	Evaluation of Interfraction Setup Uncertainty of GBM Patients Wearing TTFields (tumor treating) Tj ETQq0 0 0 rgBT <sub>2</sub> /Overlock 1 10 Tf 50 7	2.1	1
749	METTL3-mediated m6A modification of LINC00839 maintains glioma stem cells and radiation resistance by activating Wnt/ $\beta$ -catenin signaling. Cell Death and Disease, 2023, 14, .	6.3	5
750	IRP1 mediated ferroptosis reverses temozolomide resistance in glioblastoma via affecting LCN2/FPN1 signaling axis depended on NFkB2. IScience, 2023, 26, 107377.	4.1	2
751	A prognostic biomarker NRG1 promotes Uâ€™87 MG glioblastoma cell malignancy by inhibiting autophagy via ERBB2/AKT/mTOR pathway. Journal of Cellular Biochemistry, 2023, 124, 1273-1288.	2.6	1
752	Scaffold-Based (Matrigelâ„¢) 3D Culture Technique of Glioblastoma Recovers a Patient-like Immunosuppressive Phenotype. Cells, 2023, 12, 1856.	4.1	0
753	Micro-Fragmented Adipose Tissue as a Natural Scaffold for Targeted Drug Delivery in Brain Cancer. International Journal of Molecular Sciences, 2023, 24, 11530.	4.1	1
754	Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiformeâ€”a retrospective cohort study. Frontiers in Immunology, 0, 14, .	4.8	0
755	Signal-transducing adaptor protein 1 (STAP1) in microglia promotes the malignant progression of glioma. Journal of Neuro-Oncology, 0, , .	2.9	0
756	A Cholesterol Metabolic Regulated Hydrogenâ€B Bonded Organic Framework (HOF)â€B Based Biotuner for Antibody Nonâ€D Dependent Immunotherapy Tailored for Glioblastoma. Advanced Materials, 2023, 35, .	21.0	7
757	Research Progress of microRNA1281 in Different Tumors. Advances in Clinical Medicine, 2023, 13, 11468-11474.	0.0	0
758	Mesenchymal stem cells, as glioma exosomal immunosuppressive signal multipliers, enhance MDSCs immunosuppressive activity through the miR-21/SP1/DNMT1 positive feedback loop. Journal of Nanobiotechnology, 2023, 21, .	9.1	2
759	Neuromodulation for Brain Tumors: Myth or Reality? A Narrative Review. International Journal of Molecular Sciences, 2023, 24, 11738.	4.1	0
760	Circular RNA encoded MET variant promotes glioblastoma tumorigenesis. Nature Communications, 2023, 14, .	12.8	4
761	Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma. Clinical Cancer Research, 2023, 29, 4209-4218.	7.0	0
762	Brain Tumors: Development, Drug Resistance, and Sensitization â€” An Epigenetic Approach. Epigenetics, 2023, 18, .	2.7	0
763	TCAF2 is associated with the immune microenvironment, promotes pathogenesis, and impairs prognosis in glioma. Gene, 2023, 883, 147667.	2.2	2
764	Medicarpin suppresses proliferation and triggeres apoptosis by upregulation of <scp>BID</scp>, <scp>BAX</scp>, <scp>CASP3</scp>, <scp>CASP8</scp>, and <scp>CYCS</scp> in glioblastoma. Chemical Biology and Drug Design, 0, , .	3.2	0
765	Decoding key cell sub-populations and molecular alterations in glioblastoma at recurrence by single-cell analysis. Acta Neuropathologica Communications, 2023, 11, .	5.2	0

#	ARTICLE	IF	CITATIONS
766	Mapping high-grade glioma immune infiltration to 5-ALA fluorescence levels: TCGA data computation, classical histology, and digital image analysis. <i>Journal of Neuro-Oncology</i> , 2023, 164, 211-220.	2.9	1
767	COVPRIG robustly predicts the overall survival of IDH wild-type glioblastoma and highlights METTL1+ neural-progenitor-like tumor cell in driving unfavorable outcome. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	0
768	Etoricoxib-Cannabidiol Combo: Potential Role in Glioblastoma Treatment and Development of PLGA-Based Nanoparticles. <i>Pharmaceutics</i> , 2023, 15, 2104.	4.5	1
769	Neutrophil membrane-based nanotherapeutics: Propitious paradigm shift in the management of cancer. <i>Life Sciences</i> , 2023, 331, 122021.	4.3	3
770	Enhancement of Microglia Functions by Developed Nano-Immuno-Synergist to Ameliorate Immunodeficiency for Malignant Glioma Treatment. <i>Advanced Healthcare Materials</i> , 2023, 12, .	7.6	0
771	Dissection of transcriptomic and epigenetic heterogeneity of grade 4 gliomas: implications for prognosis. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	5.2	2
772	Prodrug-loaded semiconducting polymer hydrogels for deep-tissue sono-immunotherapy of orthotopic glioblastoma. <i>Biomaterials Science</i> , 2023, 11, 6823-6833.	5.4	1
773	Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice. <i>Molecular Therapy - Oncolytics</i> , 2023, 30, 238-253.	4.4	2
774	Tetraspanins predict the prognosis and characterize the tumor immune microenvironment of glioblastoma. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
775	Autophagy in combination therapy of temozolomide and IFN- $\beta$ in C6-induced glioblastoma: role of non-coding RNAs. <i>Immunotherapy</i> , 2023, 15, 1157-1169.	2.0	1
776	Intradural Intramedullary Spinal Cord Glioblastoma: A Case Report. <i>Cureus</i> , 2023, , .	0.5	0
777	Comprehensive Analysis of Ferroptosis Regulators with Regard to PD-L1 and Immune Infiltration in Low-Grade Glioma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 12880.	4.1	0
778	Recombinant SLURP-1 Inhibits Growth and Migration of U251 MG Glioma by Cell Cycle Arrest and Modulation of MAPK and AKT Signaling Pathways. <i>Russian Journal of Bioorganic Chemistry</i> , 2023, 49, 768-774.	1.0	1
779	Identify RP2 as a prognostic biomarker for glioma, facilitating glioma pathogenesis mainly via regulating tumor immunity. <i>Aging</i> , 0, , .	3.1	0
780	Advancing Glioblastoma Therapy: Promising Research in Precision Medicine. <i>Drug Delivery Letters</i> , 2023, 13, .	0.5	0
781	Exploring the Role of microRNAs in Glioma Progression, Prognosis, and Therapeutic Strategies. <i>Cancers</i> , 2023, 15, 4213.	3.7	1
782	Nanoparticle-Based Treatment in Glioblastoma. <i>Journal of Personalized Medicine</i> , 2023, 13, 1328.	2.5	1
783	High Thioredoxin Domain-Containing Protein 11 Expression Is Associated with Tumour Progression in Glioma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 13367.	4.1	0

#	ARTICLE	IF	CITATIONS
784	Characterization of tumor microenvironment in glioblastoma multiforme identifies ITGB2 as a key immune and stromal related regulator in glial cell types. Computers in Biology and Medicine, 2023, 165, 107433.	7.0	2
785	Stereotactic Radiosurgery for Contrast-Enhancing Satellite Nodules in Recurrent Glioblastoma: A Rare Case Series From a Single Institution. Cureus, 2023, , .	0.5	0
786	PI3K Signaling Pathways as a Molecular Target for Glioblastoma Multiforme. Current Protein and Peptide Science, 2024, 25, 12-26.	1.4	0
787	An Overview of Nanotherapeutic Drug Delivery Options for the Management of Glioblastoma. Journal of Nanotheranostics, 2023, 4, 323-345.	3.1	1
788	Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis. Journal of Neuro-Oncology, 2023, 164, 31-41.	2.9	3
789	3D-Printed Tumor-on-a-Chip Model for Investigating the Effect of Matrix Stiffness on Glioblastoma Tumor Invasion. Biomimetics, 2023, 8, 421.	3.3	0
790	Differential Susceptibility of Ex Vivo Primary Glioblastoma Tumors to Oncolytic Effect of Modified Zika Virus. Cells, 2023, 12, 2384.	4.1	1
791	The Present and Future of Optic Pathway Glioma Therapy. Cells, 2023, 12, 2380.	4.1	1
792	Novel Function of Cancer Stem Cell Marker ALDH1A3 in Glioblastoma: Pro-Angiogenesis through Paracrine PAI-1 and IL-8. Cancers, 2023, 15, 4422.	3.7	0
793	Radiomics Features on Magnetic Resonance Images Can Predict C5aR1 Expression Levels and Prognosis in High-Grade Glioma. Cancers, 2023, 15, 4661.	3.7	1
794	Diagnostic Approaches to Adult-Type Diffuse Glial Tumors: Comparative Literature and Clinical Practice Study. Current Oncology, 2023, 30, 7818-7835.	2.2	0
795	Radiomics: The New Promise for Differentiating Progression, Recurrence, Pseudoprogression, and Radionecrosis in Glioma and Glioblastoma Multiforme. Cancers, 2023, 15, 4429.	3.7	1
796	S100A6 is a potential diagnostic and prognostic biomarker for human glioma. Oncology Letters, 2023, 26, .	1.8	0
797	TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathways. Scientific Reports, 2023, 13, .	3.3	0
798	Next Generation of Brain Cancer Nanomedicines to Overcome the Bloodâ€‘Brain Barrier (BBB): Insights on Transcytosis, Perivascular Tumor Growth, and BBB Models. Advanced Therapeutics, 2023, 6, .	3.2	0
799	MR Perfusion Imaging for Gliomas. Magnetic Resonance Imaging Clinics of North America, 2024, 32, 73-83.	1.1	1
800	Enhancing Transcriptional Reprogramming of Mesenchymal Glioblastoma with Grainyhead-like 2 and HDAC Inhibitors Leads to Apoptosis and Cell-Cycle Dysregulation. Genes, 2023, 14, 1787.	2.4	0
801	Photodynamic therapy and associated targeting methods for treatment of brain cancer. Frontiers in Pharmacology, 0, 14, .	3.5	3

#	ARTICLE	IF	CITATIONS
802	Development of Zika Virus E Variants for Pseudotyping Retroviral Vectors Targeting Glioblastoma Cells. International Journal of Molecular Sciences, 2023, 24, 14487.	4.1	2
803	New trends in brain tumor immunity with the opportunities of lymph nodes targeted drug delivery. Journal of Nanobiotechnology, 2023, 21, .	9.1	0
804	The role of angiogenic growth factors in the immune microenvironment of glioma. Frontiers in Oncology, 0, 13, .	2.8	3
805	The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma. Frontiers in Immunology, 0, 14, .	4.8	5
806	SLC1A5 is a novel biomarker associated with ferroptosis and the tumor microenvironment: a pancancer analysis. Aging, 0, , .	3.1	0
807	PARP14 correlates with GBM proliferation and poor prognosis by elevating expression of SAMD/SAMD9L. Irish Journal of Medical Science, 0, , .	1.5	0
808	Iron oxide nanoparticles induce ferroptosis via the autophagic pathway by synergistic bundling with paclitaxel. Molecular Medicine Reports, 2023, 28, .	2.4	0
809	Focused acoustic vortex-mediated sonochemotherapy for the amplification of immunogenic cell death combined with checkpoint blockade to potentiate cancer immunotherapy. Biomaterials, 2023, 301, 122278.	11.4	4
810	Combination Drug Therapy of Glioblastoma: Lessons from 3D In Vitro Models and the Roadmap for Future Research. Advanced Therapeutics, 0, , .	3.2	0
811	Clinical advances in oncolytic virus therapy for malignant glioma: a systematic review. Discover Oncology, 2023, 14, .	2.1	1
812	Dual-Site Förster Resonance Energy Transfer Route of Upconversion Nanoparticles-Based Brain-Targeted Nanotheranostic Boosts the Near-Infrared Phototherapy of Glioma. ACS Nano, 2023, 17, 16840-16853.	14.6	8
813	Preclinical and Clinical Use of Indigenously Developed <sup>99m</sup> Tc-Diethylenetriaminepentaacetic Acid-Bis-Methionine: <sup>125</sup> I-Type Amino Acid Transporter 1-Targeted Single Photon Emission Computed Tomography Radiotracer for Glioma Management. ACS Pharmacology and Translational Science, 2023, 6, 1233-1247.	4.9	2
814	CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma. Immunity, 2023, 56, 2086-2104.e8.	14.3	9
815	Spatial distribution and functional relevance of FGFR1 and FGFR2 expression for glioblastoma tumor invasion. Cancer Letters, 2023, 571, 216349.	7.2	2
816	Dual drug-loaded calabash-like nanomotor as an active therapeutic for enhanced chemo-photothermal therapy of orthotopic glioblastoma. Chemical Engineering Journal, 2023, 473, 145413.	12.7	2
817	Knowledge structure and hotspots research of glioma immunotherapy: a bibliometric analysis. Frontiers in Oncology, 0, 13, .	2.8	0
818	Preoperative vascular heterogeneity based on dynamic susceptibility contrast MRI in predicting spatial pattern of locally recurrent high-grade gliomas. European Radiology, 2024, 34, 1982-1993.	4.5	2
819	Neuropsychological impairment in primary malignant brain tumor patients with awake craniotomy: a hospital-based registration study. Journal of Neuro-Oncology, 2023, 164, 483-491.	2.9	0

#	ARTICLE	IF	CITATIONS
820	Conducting 2D and 3D QSAR Analyses and Molecular Docking Studies of Analogues of 2-(1-(1,3,4-thiadiazol-2-yl)piperidin-4-yl)ethan-1-ol with the Aim of Identifying Promising Drug Candidates for Targeting Glioblastoma. Letters in Drug Design and Discovery, 2024, 21, 602-658.	0.7	0
821	Clinical Value of a Nomogram Model Based on Apparent Diffusion Coefficient Values Within 1Âcm of the Tumor Cavity to Predict Postoperative Progression of Glioma. World Neurosurgery, 2023, , .	1.3	0
822	Tumoral and peritumoral vascularization of brain tumours: a study comparing an intraoperative ultrasensitive Doppler and a preoperative first-pass perfusion MRI. Neurochirurgie, 2023, 69, 101493.	1.2	0
824	Targeting MYH9 represses USP14-mediated NAP1L1 deubiquitination and cell proliferation in glioma. Cancer Cell International, 2023, 23, .	4.1	0
825	Advancements in surgical management of glioblastoma: current trends and promising future directions. International Neurological Journal, 2023, 19, 155-159.	0.2	0
827	Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188996.	7.4	1
828	The use of bevacizumab in primary malignant tumors of the central nervous system: A single-center experience. Medicine (United States), 2023, 102, e34286.	1.0	2
829	Prognostic risk of immune-associated signature in the microenvironment of brain gliomas. Frontiers in Genetics, 0, 14, .	2.3	0
830	Unleashing the Potential of Natural Killer Cells in Immunotherapy for Glioblastoma and Brain Tumors. , 2023, , .		0
831	<b>CNS distribution of panobinostat in preclinical models to guide dosing for pediatric brain tumors</b>. Journal of Pharmacology and Experimental Therapeutics, 0, , JPET-AR-2023-001826.	2.5	0
832	Genomeâ€wide <scp>DNA</scp> methylation analysis identifies potent <scp>CpG</scp> signature for temzolomide response in <scp>nonâ€Gâ€CIMP</scp> glioblastomas with unmethylated <scp><i>MGMT</i></scp> promoter: <scp><i>MGMT</i></scp>â€dependent roles of <scp><i>GPR81</i></scp>. CNS Neuroscience and Therapeutics, 0, , .	3.9	0
833	Tapirira guianensis is Selectively Cytotoxic, Induces Apoptosis to the Glioblastoma and Decreases Tumor Growth and Angiogenesis in vivo. Planta Medica, 0, , .	1.3	0
834	Transcriptomic Characterization of Copper-Binding Proteins for Predicting Prognosis in Glioma. Brain Sciences, 2023, 13, 1460.	2.3	0
835	Nitric Oxide Synthase Inhibition Prevents Cell Proliferation in Glioblastoma. Journal of Molecular Neuroscience, 0, , .	2.3	0
836	Tracking tumor evolution during the first-line treatment in brain glioma via serial profiling of cell-free tumor DNA from tumor in situ fluid. Frontiers in Oncology, 0, 13, .	2.8	0
837	Non-animal glioblastoma models for personalized treatment. Heliyon, 2023, 9, e21070.	3.2	0
838	Expression profiles and function prediction of tRNA-derived fragments in glioma. BMC Cancer, 2023, 23, .	2.6	0
839	Inorganic and metal-based nanoparticles. , 2024, , 203-235.		0

#	ARTICLE	IF	CITATIONS
840	Progesterone Receptor Membrane Component 1 (PGRMC1) Modulates Tumour Progression, the Immune Microenvironment and the Response to Therapy in Glioblastoma. <i>Cells</i> , 2023, 12, 2498.	4.1	0
841	Tracking tumor alteration in glioma through serum fibroblast activation protein combined with image. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
842	Brain tumours: Non-invasive techniques to treat invasive pathologies. <i>Annales Pharmaceutiques Francaises</i> , 2024, 82, 229-235.	1.0	0
843	Extra-Neural Metastases of Glioblastoma: A Case Series. <i>Cureus</i> , 2023, , .	0.5	0
844	Editorial for “Handling Missing <scp>MRI</scp> Data in Brain Tumors Classification Tasks: Usage of Synthetic Images vs. Duplicate Images and Empty Images” <i>Journal of Magnetic Resonance Imaging</i> , 0, , .	3.4	0
845	Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma. <i>Science Advances</i> , 2023, 9, .	10.3	0
846	Treatment-prognostication-adjustment a new therapeutic idea by analyzing T cell immune checkpoint in tumor microenvironment by algorithm: A bibliometric analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	0
847	Preoperative stereotactic radiosurgery as neoadjuvant therapy for resectable brain tumors. <i>Journal of Neuro-Oncology</i> , 2023, 165, 21-28.	2.9	0
848	Rehabilitation Exercises Supported by Monitor-Augmented Reality for Patients with High-Grade Glioma Undergoing Radiotherapy: Results of a Randomized Clinical Trial. <i>Journal of Clinical Medicine</i> , 2023, 12, 6838.	2.4	0
849	Development and optimisation of in vitro sonodynamic therapy for glioblastoma. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
850	Minocycline as a prospective therapeutic agent for cancer and non-cancer diseases: a scoping review. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 0, , .	3.0	0
851	Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications. <i>Journal of Clinical Medicine</i> , 2023, 12, 7442.	2.4	2
852	Ferritinâ€Based Nanocomposite Hydrogel Promotes Tumor Penetration and Enhances Cancer Chemoimmunotherapy. <i>Advanced Science</i> , 0, , .	11.2	1
856	In vivo MRS study of long-term effects of traumatic intracranial injection of a culture medium in mice. <i>Vavilovskii Zhurnal Genetiki i Seleksii</i> , 2023, 27, 633-640.	1.1	0
857	The Clinical Relevance and Functional Implications of Thymosin Beta-10 in Glioma. <i>Genetical Research</i> , 2023, 2023, 1-13.	0.9	0
858	Collagen and derivatives-based materials as substrates for the establishment of glioblastoma organoids. <i>International Journal of Biological Macromolecules</i> , 2024, 254, 128018.	7.5	0
859	Neuronal Activity Promotes Glioma Progression by Inducing Proneural-to-Mesenchymal Transition in Glioma Stem Cells. <i>Cancer Research</i> , 2024, 84, 372-387.	0.9	2
860	Vasari-Based Features Nomogram to Predict the Tumor-Infiltrating CD8+ T Cell Levels in Glioblastoma. <i>Academic Radiology</i> , 2023, , .	2.5	0



#	ARTICLE	IF	CITATIONS
861	Anti-Glioma Effects of Ligustilide or n-Butylphthalide on Their Own and the Synergistic Effects with Temozolomide via PI3K/Akt Signaling Pathway. <i>OncoTargets and Therapy</i> , 0, Volume 16, 983-994.	2.0	0
862	Micro/nanosystems for controllable drug delivery to the brain. <i>Innovation(China)</i> , 2024, 5, 100548.	9.1	0
864	Heterogeneity matching and IDH prediction in adult-type diffuse gliomas: a DKI-based habitat analysis. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
866	Patientâ€Derived Microphysiological Systems for Precision Medicine. <i>Advanced Healthcare Materials</i> , 0, , .	7.6	0
867	Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence. <i>Medicine (United States)</i> , 2023, 102, e36421.	1.0	1
868	Marital Status as an Independent Prognostic Factor in Patients with Glioblastoma: A Population-Based Study. <i>World Neurosurgery</i> , 2024, 182, e559-e569.	1.3	0
869	CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastoma. , 2023, 11, e007481.		0
870	Total DNA methylation profile in assessing the MGMT gene promoter status in malignant gliomas. <i>Zhurnal Voprosy Neirokhirurgii Imeni N N Burdenko</i> , 2023, 87, 52.	0.2	0
872	Ganciclovir as a potential treatment for glioma: a systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 0, , .	2.9	0
873	Investigating the causal impact of gut microbiota on glioblastoma: aÂbidirectional Mendelian randomization study. <i>BMC Genomics</i> , 2023, 24, .	2.8	1
874	Circ_0027446 promotes malignant development of glioblastoma by interacting with miR-346 to up-regulate PGK1. <i>Metabolic Brain Disease</i> , 0, , .	2.9	0
875	Cell Membrane-Coated Oncolytic Adenovirus for Targeted Treatment of Glioblastoma. <i>Nano Letters</i> , 2023, 23, 11120-11128.	9.1	2
876	Self-Cross-Linked Chitosan/Albumin-Bound Nanoparticle Hydrogel for Inhibition of Postsurgery Malignant Glioma Recurrence. <i>ACS Applied Materials &amp; Interfaces</i> , 0, , .	8.0	0
877	Integrative analysis of transcriptome and proteome profiles in primary and recurrent glioblastoma. <i>Proteomics - Clinical Applications</i> , 0, , .	1.6	0
878	Exosome-transmitted ANGPTL1 suppresses angiogenesis in glioblastoma by inhibiting the VEGFA/VEGFR2/Akt/eNOS pathway. <i>Journal of Neuroimmunology</i> , 2024, 387, 578266.	2.3	0
879	Regulation of cancer stem cells and immunotherapy of glioblastoma (Review). <i>Biomedical Reports</i> , 2023, 20, .	2.0	0
880	Soft Bioelectronics for Neuroengineering: New Horizons in the Treatment of Brain Tumor and Epilepsy. <i>Advanced Healthcare Materials</i> , 0, , .	7.6	1
881	Intranasal administration of molecular-gated mesoporous nanoparticles to increase ponatinib delivery to the brain. <i>Nanomedicine</i> , 2023, 18, 1799-1813.	3.3	0

#	ARTICLE	IF	CITATIONS
882	Therapeutic applications of thymosin peptides: a patent landscape 2018-present. Expert Opinion on Therapeutic Patents, 2023, 33, 865-873.	5.0	0
883	Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies. Medical Sciences (Basel, Switzerland), 2024, 12, 1.	2.9	0
884	The contribution of proteoglycans to heterogeneity and temozolomide resistance of glioblastoma cells. Journal of Cancer Metastasis and Treatment, 0, , .	0.8	0
885	MRI Image Segmentation of Brain Tumor Based on Res-UNet. , 2023, , .		0
887	Glioblastoma in an old patient treated with a combination of tumor-treating fields and standard chemoradiotherapy: A case report. Glioma (Mumbai, India), 2023, 6, 19-22.	0.1	0
888	Multiparametric Analysis Combining DSC-MR Perfusion and [18F]FET-PET is Superior to a Single Parameter Approach for Differentiation of Progressive Glioma from Radiation Necrosis. Clinical Neuroradiology, 0, , .	1.9	0
889	Engineered Microglia Exosomes Coated Highly Twisting AIE Photothermal Agents to Efficiently Cross Blood-Brain Barrier for Mild Photothermal Immune Checkpoint Blockade Therapy in Glioblastoma. Advanced Functional Materials, 0, , .	14.9	0
890	Hypoxia induced Galectin-8 maintains stemness in glioma stem cells via autophagy regulation. Neuro-Oncology, 0, , .	1.2	0
891	Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks. Journal of Experimental and Clinical Cancer Research, 2024, 43, .	8.6	1
892	A glycosylation-related gene signature predicts prognosis, immune microenvironment infiltration, and drug sensitivity in glioma. Frontiers in Pharmacology, 0, 14, .	3.5	1
893	ITGB4 upregulation is associated with progression of lower grade glioma. Scientific Reports, 2024, 14, .	3.3	0
894	The TGF- $\beta$ Family in Glioblastoma. International Journal of Molecular Sciences, 2024, 25, 1067.	4.1	0
895	Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy. Frontiers in Immunology, 0, 14, .	4.8	0
896	Borneol promotes autophagic degradation of HIF-1 $\alpha$ and enhances chemotherapy sensitivity in malignant glioma. PeerJ, 0, 12, e16691.	2.0	0
897	DENDRITIC CELLS IN GLIOBLASTOMA TREATMENT: A MODERN VIEW OF THE PROBLEM AND OWN EXPERIENCE. Experimental Oncology, 2024, 45, 282-296.	0.1	0
898	Integrated bioinformatics analysis and experimental validation identified CDCA families as prognostic biomarkers and sensitive indicators for rapamycin treatment of glioma. PLoS ONE, 2024, 19, e0295346.	2.5	0
899	Identification and validation of prognostic genes and immune landscape signatures based on a fatty acid oxidation-related risk score model in glioma. Oncology Letters, 2024, 27, .	1.8	0
900	Survival Impact of Combined Biguanide and Temozolomide in Glioblastoma Preclinical Models: A Systematic Review and Meta-Analysis. World Neurosurgery, 2024, 183, 239-245.e2.	1.3	0

#	ARTICLE	IF	CITATIONS
901	Kinin Receptors and Kinin-Related Gene Expression in Astrocytic Brain Tumors. <i>Cancers</i> , 2024, 16, 241.	3.7	0
902	P129, a pyrazole ring-containing isolongifolanone-derivate: synthesis and investigation of anti-glioma action mechanism. <i>Discover Oncology</i> , 2024, 15, .	2.1	0
903	Breaking Barriers: A Future Perspective on Glioblastoma Therapy with mRNA-Based Immunotherapies and Oncolytic Viruses. <i>Vaccines</i> , 2024, 12, 61.	4.4	0
904	Arsenic trioxide induces ferroptosis in neuroblastoma by mediating <scp>GPX4</scp> transcriptional inhibition. <i>Clinical and Translational Science</i> , 2024, 17, .	3.1	0
905	Reconstructing Disease Histories in Huge Discrete State Spaces. <i>KI - Kunstliche Intelligenz</i> , 0, , .	3.2	1
906	ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines. <i>Oncotarget</i> , 2024, 15, 1-18.	1.8	0
907	Chronic stress as an emerging risk factor for the development and progression of glioma. <i>Chinese Medical Journal</i> , 2024, 137, 394-407.	2.3	0
909	Microneedle Patch Delivery of PLCG1-siRNA Efficient Enhanced Temozolomide Therapy for Glioblastoma. <i>Biomacromolecules</i> , 2024, 25, 655-665.	5.4	0
910	Gint4.T-siHDGF chimera-capped mesoporous silica nanoparticles encapsulating temozolomide for synergistic glioblastoma therapy. <i>Biomaterials</i> , 2024, 306, 122479.	11.4	0
911	Tumor-associated microenvironment, PD-L1 expression and their relationship with immunotherapy in glioblastoma, IDH-wild type: A comprehensive review with emphasis on the implications for neuropathologists. <i>Pathology Research and Practice</i> , 2024, 254, 155144.	2.3	0
912	The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-Myc-UHRF1 interactions. <i>Journal of Experimental and Clinical Cancer Research</i> , 2024, 43, .	8.6	0
913	Proline Metabolism in WHO G4 Gliomas Is Altered as Compared to Unaffected Brain Tissue. <i>Cancers</i> , 2024, 16, 456.	3.7	0
914	Stabilization of KPNB1 by deubiquitinase USP7 promotes glioblastoma progression through the YBX1-NLGN3 axis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2024, 43, .	8.6	0
915	Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions. <i>Cells</i> , 2024, 13, 218.	4.1	1
916	Immune-related lncRNAs signature and radiomics signature predict the prognosis and immune microenvironment of glioblastoma multiforme. <i>Journal of Translational Medicine</i> , 2024, 22, .	4.4	0
917	EPHB2 as a key mediator of glioma progression: Insights from microenvironmental receptor ligand-related prognostic gene signature. <i>Genomics</i> , 2024, 116, 110799.	2.9	0
919	Copy number gain of FAM131B-AS2 promotes the progression of glioblastoma by mitigating replication stress. <i>Neuro-Oncology</i> , 0, , .	1.2	0
920	Exploring the <i>in vitro</i> potential of royal jelly against glioblastoma and neuroblastoma: impact on cell proliferation, apoptosis, cell cycle, and the biomolecular content. <i>Analyst, The</i> , 2024, 149, 1872-1884.	3.5	0

#	ARTICLE	IF	CITATIONS
921	Glioblastoma Margin as a Diffusion Barrier Revealed by Photoactivation of Plasmonic Nanovesicles. Nano Letters, 2024, 24, 1570-1578.	9.1	0
922	Changes in the Epidemiologic Pattern of Primary CNS Tumors in Response to the Aging Population: An Updated Nationwide Cancer Registry Data in the Republic of Korea. JCO Global Oncology, 2024, , .	1.8	0
923	Selfâ€Disassembling and Oxygenâ€Generating Porphyrinâ€Lipoprotein Nanoparticle for Targeted Glioblastoma Resection and Enhanced Photodynamic Therapy. Advanced Materials, 2024, 36, .	21.0	0
924	Exploring the Potential of Phytochemicals Derived From Indian Medicinal Plants for Management and Treatment of Glioblastoma Multiforme Based on In Vitro Studies. Journal of Herbal Medicine, 2024, 44, 100856.	2.0	0
925	Molecular and immunological features of TREM1 and its emergence as a prognostic indicator in glioma. Frontiers in Immunology, 0, 15, .	4.8	0
926	Basic Transcription Factor 3 Like 4 Enhances Malignant Phenotypes through Modulating Tumor Cell Function and Immune Microenvironment in Glioma. American Journal of Pathology, 2024, 194, 772-784.	3.8	0
927	Current Photodynamic Therapy for Glioma Treatment: An Update. Biomedicines, 2024, 12, 375.	3.2	0
928	Early investigation of a novel SI306 theranostic prodrug for glioblastoma treatment. Drug Development Research, 2024, 85, .	2.9	0
929	Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives. International Journal of Molecular Sciences, 2024, 25, 2108.	4.1	0
930	Glioblastoma-Associated Mesenchymal Stem/Stromal Cells and Cancer-Associated Fibroblasts: Partners in Crime?. International Journal of Molecular Sciences, 2024, 25, 2285.	4.1	0
931	Cathepsin B-Responsive Programmed Brain Targeted Delivery System for Chemo-Immunotherapy Combination Therapy of Glioblastoma. ACS Nano, 2024, 18, 6445-6462.	14.6	0
932	Let-7b-5p promotes triptolide-induced growth-inhibiting effects in glioma by targeting IGF1R. Naunyn-Schmiedeberg's Archives of Pharmacology, 0, , .	3.0	0
933	Identification of a novel glioblastoma multiforme molecular subtype with poor prognosis and high immune infiltration based on oxidative stress-related genes. Medicine (United States), 2024, 103, e35828.	1.0	0
934	Downregulating DNA methyltransferase 3B by suppressing the PI3K/Akt signaling pathway enhances the chemosensitivity of glioblastoma to temozolomide. Molecular Neurobiology, 0, , .	4.0	0
935	Glioblastoma Therapy: Past, Present and Future. International Journal of Molecular Sciences, 2024, 25, 2529.	4.1	0
936	Identifying PLAUR as a Pivotal Gene of Tumor Microenvironment and Regulating Mesenchymal Phenotype of Glioblastoma. Cancers, 2024, 16, 840.	3.7	0
937	Exosomes in Glioma: Unraveling Their Roles in Progression, Diagnosis, and Therapy. Cancers, 2024, 16, 823.	3.7	0
938	Modification of BCLX pre-mRNA splicing has antitumor efficacy alone or in combination with radiotherapy in human glioblastoma cells. Cell Death and Disease, 2024, 15, .	6.3	0

#	ARTICLE	IF	CITATIONS
939	Optimizing adjuvant treatment options for patients with glioblastoma. <i>Frontiers in Neurology</i> , 0, 15, .	2.4	0
940	Development and Optimisation of Tumour Treating Fields (TTFields) Delivery within 3D Primary Glioma Stem Cell-like Models of Spatial Heterogeneity. <i>Cancers</i> , 2024, 16, 863.	3.7	0
941	Effectively Î±-Terpineol Suppresses Glioblastoma Aggressive Behavior and Downregulates KDELC2 Expression. <i>Phytomedicine</i> , 2024, 127, 155471.	5.3	0
942	Engineered exosomes with enhanced stability and delivery efficiency for glioblastoma therapy. <i>Journal of Controlled Release</i> , 2024, 368, 170-183.	9.9	0
943	The prognostic utility of temporalis muscle thickness measured on magnetic resonance scans in patients with intra-axial malignant brain tumours: A systematic review and meta-analysis. <i>World Neurosurgery</i> : X, 2024, 22, 100318.	1.1	0
944	Prediction Model of Recurrence of LGG Based on Random Survival Forest. <i>Statistics and Applications</i> , 2024, 13, 151-163.	0.1	0
946	CPLX2 is a novel tumor suppressor and improves the prognosis in glioma. <i>Journal of Neuro-Oncology</i> , 2024, 167, 63-74.	2.9	0
947	ICBP90, an epigenetic regulator, induces DKK3 promoter methylation, promotes glioma progression, and reduces sensitivity to cis-platinum. <i>Experimental Cell Research</i> , 2024, 436, 113976.	2.6	0
948	ImmunoPET imaging of TIGIT in the glioma microenvironment. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
950	Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers. <i>International Journal of Molecular Sciences</i> , 2024, 25, 3040.	4.1	0
951	RND1 inhibits epithelial-mesenchymal transition and temozolomide resistance of glioblastoma via AKT/GSK3-Î² pathway. <i>Cancer Biology and Therapy</i> , 2024, 25, .	3.4	0
952	Exploring the causal relationship between antihypertensive drugs and glioblastoma by combining drug target Mendelian randomization study, <sc>eQTL</sc> colocalization, and singleâ€cell <sc>RNA</sc> sequencing. <i>Environmental Toxicology</i> , 0, , .	4.0	0
953	Induction of glioblastoma invasion triggered by system Xcâˆ’-mediated glutamate release. <i>Molecular and Cellular Toxicology</i> , 0, , .	1.7	0
954	Artificial intelligence-based MRI radiomics and radiogenomics in glioma. <i>Cancer Imaging</i> , 2024, 24, .	2.8	0
955	Upregulation of HLAâ€II related to LAGâ€3<sup>+</sup>CD4<sup>+</sup> T cell infiltration is associated with patient outcome in human glioblastoma. <i>Cancer Science</i> , 0, , .	3.9	0
956	Biomimetic nanocarriers loaded with temozolomide by cloaking brain-targeting peptides for targeting drug delivery system to promote anticancer effects in glioblastoma cells. <i>Heliyon</i> , 2024, 10, e28256.	3.2	0
957	High-performance presurgical differentiation of glioblastoma and metastasis by means of multiparametric neurite orientation dispersion and density imaging (NODDI) radiomics. <i>European Radiology</i> , 0, , .	4.5	0
958	Bloodâ€“Brain Barrier Penetrating Nanovehicles for Interfering with Mitochondrial Electron Flow in Glioblastoma. <i>ACS Nano</i> , 2024, 18, 9511-9524.	14.6	0

#	ARTICLE	IF	CITATIONS
959	WTAP regulates the production of reactive oxygen species, promotes malignant progression, and is closely related to the tumor microenvironment in glioblastoma. Aging, 2024, 16, 5601-5617.	3.1	0
960	MRI-derived radiomics assessing tumor-infiltrating macrophages enable prediction of immune-phenotype, immunotherapy response and survival in glioma. Biomarker Research, 2024, 12, .	6.8	0
961	Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI). Npj Precision Oncology, 2024, 8, .	5.4	0
962	Creation of signatures and identification of molecular subtypes based on disulfidptosis-related genes for glioblastoma patients' prognosis and immunological activity. Asian Journal of Surgery, 2024, , .	0.4	0
963	Comparative Study of Postmortem MRI and Pathological Findings in Malignant Brain Tumors. Cureus, 2024, , .	0.5	0
964	X-ray Activated Nanoprodrug for Visualization of Cortical Microvascular Alterations and NIR-II Image-Guided Chemo-Radiotherapy of Glioblastoma. Nano Letters, 2024, 24, 3727-3736.	9.1	0
965	Juglone induces ferroptosis in glioblastoma cells by inhibiting the Nrf2-GPX4 axis through the phosphorylation of p38MAPK. Chinese Medicine, 2024, 19, .	4.0	0
966	Loss of PTPRS elicits potent metastatic capability and resistance to temozolomide in glioblastoma. Molecular Carcinogenesis, 0, , .	2.7	0
967	Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming. Nature Cancer, 0, , .	13.2	0
968	DNA damage-regulated autophagy modulator 1 prevents glioblastoma cells proliferation by regulating lysosomal function and autophagic flux stability. Experimental Cell Research, 2024, 437, 114016.	2.6	0
969	Tumor treating fields in glioblastoma: long-term treatment and high compliance as favorable prognostic factors. Frontiers in Oncology, 0, 14, .	2.8	0